<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0013.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0015.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h102" class="calibre8"></a><a id="page_8-1" class="calibre8"></a><a href="part0003.html#rh113" class="calibre8">APPROACH TO RHEUMATIC DISEASE</a></h2>
<p class="h">Major categories of inflammatory rheumatic disease</p>
<p class="noindent1">• <b class="calibre7">Inflammatory arthritis</b>: crystalline (gout, CPPD), RA, spondyloarthritis, adult-onset Still’s</p>
<p class="noindent1">• <b class="calibre7">Connective tissue disease</b>: SLE, Sjögren’s, scleroderma, myositides (DM, PM), MCTD</p>
<p class="noindent1">• <b class="calibre7">Vasculitis</b>: large (GCA, Takayasu’s); medium (PAN); small (ANCA, IgA, cryo); Behçet’s</p>
<p class="noindent1">• <b class="calibre7">Other</b>: IgG4-related disease, autoinflammatory disease (familial Mediterranean fever, TNF receptor-associated periodic syndrome, VEXAS = vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic), sarcoid (see “ILD”), HLH/MAS, relapsing polychondritis</p>
<p class="h">Approach to patient with joint pain</p>
<p class="noindent1">• <b class="calibre7">Articular</b> vs. <b class="calibre7">periarticular</b> (bursitis, tendinitis) source of pain: typically active ROM more painful than passive ROM in periarticular process</p>
<p class="noindent1">• <b class="calibre7">Inflammatory</b> vs. <b class="calibre7">noninflammatory</b> pain: <i class="calibre6">features of inflammatory arthropathy</i> include joint swelling, warmth or redness, prolonged morning stiffness (&gt;30 min), improvement of pain/stiffness w/ motion/exercise. Assess for extra-articular features.</p>
<p class="noindent1">• Physical exam: localize complaint, identify signs of inflammation, and assess number and pattern of affected joints.</p>
<p class="imaget"><img src="../images/00098.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn169-a" class="calibre8"></a>a</sup>May initially present as arthralgia w/o overt arthritis. <sup class="calibre22"><a id="rfn169-b" class="calibre8"></a>b</sup>Range of motion of joint or joint a/w bursa or tendon.</p>
<div class="cap">
<p class="caption"><a id="fig8-1" class="calibre4"></a><b class="calibre7">Figure 8-1</b> Approach to arthritis</p>
<p class="imagef1"><img src="../images/00099.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="imaget"><img src="../images/00100.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn169-s4" class="calibre8"></a>*</sup>WBC count of aspirated fluid in septic bursitis often &lt; WBC count in septic arthritis.</p>
<p class="h">Imaging features of major arthritides</p>
<p class="noindent1">• <b class="calibre7">OA:</b> plain films: asym joint space narrowing (JSN), <b class="calibre7">osteophytes</b>, subchondral sclerosis &amp; cysts; subchondral “gull-wing” erosions may be seen in less-common erosive OA; MRI may show early disease not seen on plain films; U/S ≈ MRI for structural damage ⊖</p>
<p class="noindent1"><a id="page_8-2" class="calibre4"></a>• <b class="calibre7">RA:</b> plain films: symmetric JSN, early = periarticular <b class="calibre7">osteopenia;</b> late = marginal <b class="calibre7">erosions</b>; subluxations; MRI &amp; U/S can detect early and subclinical disease; MRI ≈ U/S for erosions</p>
<p class="noindent1">• <b class="calibre7">Gout:</b> plain films: early = nonspec swelling; late = <b class="calibre7">tophus</b>, joint erosions w/ overhanging edges; U/S for detection of microtophi (double-contour sign); dual-energy CT (DECT): identify articular/periarticular UrA deposits vs. calcium deposits; MRI ≈ U/S for erosions</p>
<p class="noindent1">• <b class="calibre7">Spondyloarthritis:</b> e/o <b class="calibre7">sacroiliitis</b>: plain films: early = pseudo-widening SI joint space, late = sclerosis, erosions, <b class="calibre7">ankylosis;</b> SI MRI ↑ Se for early Δ; U/S ≈ MRI to detect enthesitis</p>
<p class="imaget"><img src="../images/00101.jpeg" alt="" class="calibre5"/></p>
<p class="h1cr">I<small class="calibre31">NFLAMMATORY</small> M<small class="calibre31">ARKER</small> &amp; A<small class="calibre31">UTOANTIBODY</small> T<small class="calibre31">ESTING</small></p>
<p class="h">Inflammatory markers <span class="r1">(</span><span class="r2">Mod Rheumatol</span> <span class="r1">2009;19:469;</span> <span class="r2">NEJM</span> <span class="r1">1999;340:448)</span></p>
<p class="noindent1">• <b class="calibre7">ESR:</b> <i class="calibre6">indirect</i> measure of inflammation [↑ RBC aggregation due to acute-phase proteins (fibrinogen, Ig)]; slow to rise; may ↑ w/ age, preg., anemia, obesity, ESRD. Ddx for &gt;100: malig. esp. MM, lymphoma; GCA or other vasculitis; endocarditis, TB, osteomyelitis.</p>
<p class="noindent1">• <b class="calibre7">CRP:</b> <i class="calibre6">direct</i> measure of inflammation (protein produced by liver, part of innate immune system); <i class="calibre6">typically rises and falls before the ESR</i> w/ treatment/resolution of process</p>
<p class="h">Autoantibody testing <span class="r1">(</span><span class="r2">Best Pract Res Clin Rheumatol</span> <span class="r1">2014;28:907)</span></p>
<p class="noindent1">• ANA (anti-nuclear Ab): <i class="calibre6">screening test</i> for Ab directed against nuclear proteins.</p>
<p class="noindent1">• Order ANA only when <i class="calibre6">clinical suspicion for CTD</i> b/c nonspecific: 1:40 (very low ⊕, 25–30% of healthy Pts); 1:80 (low ⊕, 10–15% of healthy Pts); ≥1:160 (⊕, 5% of healthy Pts). May be ⊕ in Pts prior to clin manifest <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:1526;</span> <span class="r2">Arthritis Res Ther</span> <span class="r1">2011;13:1)</span>.</p>
<p class="noindent1">• If ANA ⊕ and high clinical suspicion for CTD, consider testing for Ab against dsDNA, Smith, Ro/La, RNP, Scl-70 and myositis-specific Abs (<i class="calibre6">highly specific</i> for various CTD)</p>
<p class="noindent1">• ANA does <i class="calibre6">not</i> correlate well w/ disease activity, ∴ no clinical value in serial testing</p>
<p class="noindent1">• ANA also ⊕ in: AIH, PBC, thyroid disease, certain infxns and malignancies, IBD, IPF</p>
<p class="noindent1">• RF and anti-CCP (see “Rheumatoid Arthritis”)</p>
<p class="h1cr">D<small class="calibre31">DX</small> &amp; A<small class="calibre31">PPROACH</small> <small class="calibre31">TO</small> C<small class="calibre31">OMMON</small> I<small class="calibre31">NPATIENT</small> R<small class="calibre31">HEUM</small> P<small class="calibre31">RESENTATIONS</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre34"/>
<col class="calibre33"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Rheum Ddx</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Rheum Lab w/up (+ ANA)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">FUO</p></td>
<td class="th1"><p class="tbody">GCA/PMR, AOSD, SLE, inflamm arthr, Taka- yasu, PAN, ANCA ⊕ vasc, cryo, HSP, VEXAS</p></td>
<td class="th1"><p class="tbody">ESR, CRP, RF, ANCA, ± cryo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Pulm HTN</p></td>
<td class="th1"><p class="tbody">Scleroderma (limited &gt;diffuse), MCTD, SLE, PM/DM (less common)</p></td>
<td class="th1"><p class="tbody">Scl-70, centromere, RNA Pol III, RNP</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">DAH</p></td>
<td class="th1"><p class="tbody">ANCA ⊕ vasc, Goodpasture’s, SLE, APS</p></td>
<td class="th1"><p class="tbody">ANCA, GBM, C3/C4, APLA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">ILD</p></td>
<td class="th1"><p class="tbody">Scleroderma (diffuse &gt;limited), sarcoid, RA, DM, PM, antisynthetase syndrome, Sjögren’s, MCTD, SLE (esp. pleura), ANCA ⊕ vasc (esp. MPA)</p></td>
<td class="th1"><p class="tbody">Scl-70, RF/CCP, CK, aldolase, ± myositis specific Abs, Jo-1, Ro/La, ANCA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Pleuro- pericarditis</p></td>
<td class="th1"><p class="tbody">SLE, scleroderma, RA, MCTD, DM/PM, ANCA ⊕ vasc, Sjögren’s, AOSD, PAN</p></td>
<td class="th1"><p class="tbody">dsDNA, RF/CCP, Sm, Ro/La, Scl-70, RNP, ANCA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">AKI + active sed. or CTD s/s</p></td>
<td class="th1"><p class="tbody">SLE (GN or nephrotic), ANCA ⊕ vasc (GN), scleroderma renal crisis, Sjögren’s (RTA/TIN), PAN (infarct), HSP, Goodpasture’s, cryo, APS</p></td>
<td class="th1"><p class="tbody">dsDNA, Sm, Ro/La, RNP, C3/C4, Scl-70, RNA Pol III, ANCA, GBM, cryos, APLA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neuropathy</p></td>
<td class="th1"><p class="tbody">ANCA ⊕ vasc, SLE, Sjögren’s, cryo, sarcoid, RA, PAN</p></td>
<td class="th1"><p class="tbody">Ro/La, ANCA, cryo RF/CCP, HCV, HBV</p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h103" class="calibre8"></a><a id="page_8-3" class="calibre8"></a><a href="part0003.html#rh114" class="calibre8">RHEUMATOID ARTHRITIS (RA)</a></h2>
<p class="h">Definition &amp; epidemiology <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2016;388:2023)</span></p>
<p class="noindent1">• Chronic, symmetric, and potentially destructive inflammatory polyarthritis characterized by proliferative synovial tissue (pannus) formation in affected joints</p>
<p class="noindent1">• Pathogenesis involves overproduction of TNF, IL-1, and IL-6 (∴ used as drug targets)</p>
<p class="noindent1">• Risk stems from combination of genetics (~50% of risk), environmental influences (eg, smoking, silica dust), and Pt factors (periodontal disease, Δs in gut microbiome)</p>
<p class="noindent1">• HLA-DRB1 haplotype a/w disease suscept., severity, &amp; response to Rx <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2015;313:1645)</span></p>
<p class="noindent1">• Prevalence = 1/100 adults and 1/20 ♀ &gt;70 y; ♀ to ♂ ratio = 3:1; peak incidence 50–75 y</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2018;320:1360)</span></p>
<p class="noindent1">• Usually insidious onset <b class="calibre7">pain</b>, <b class="calibre7">swelling</b>, &amp; impaired function of joints w/ prolonged <b class="calibre7">morning stiffness</b> for ≥6 wk (typically PIPs, MCPs, wrists, knees, ankles, MTPs, cervical spine)</p>
<p class="noindent1">• Typically polyarticular (60% small joints, 30% large joints, 10% both), may be monoarticular (knee, shoulder, wrist) early in course; rheumatoid joints more susceptible to infection</p>
<p class="noindent1">• Joint deformities: <b class="calibre7">ulnar deviation</b>, <b class="calibre7">swan neck</b> (MCP flexion, PIP hyperextension, DIP flexion), <b class="calibre7">boutonnière</b> (PIP flexion, DIP hyperextension), <b class="calibre7">cock-up deformities</b> (toes)</p>
<p class="noindent1">• <b class="calibre7">C1–C2 instability</b> → myelopathy, ∴✓ C-spine flex/ext films prior to elective intubation</p>
<p class="noindent1">• Constitutional symptoms: <i class="calibre6">low-grade</i> fever, weight loss, malaise</p>
<p class="noindent1">• <b class="calibre7">Extra-articular manifestations</b> (18–41% of Pts) can occur at any time; ↑ frequency in seropositive (⊕ RF or anti-CCP) and w/ active disease <span class="r1">(</span><span class="r2">Autoimmun Rev</span> <span class="r1">2021;20:102776)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Extra-Articular Manifestations</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Skin</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Rheumatoid nodules</b> (20–30%, usually sero ⊕): extensor surface, bursae; can be in lung, heart, sclera</p>
<p class="tbody">Raynaud’s, pyoderma gangrenosum, cutan. vasculitis (ulcers, purpura, etc.)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulm</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">ILD</b> (a/w <i class="calibre6">MUC5B</i> mutations), airway disease, pleuritis, effusions (low glc), nodules, pulm HTN; precedes joint sx in 20% of cases; RA med toxicity (MTX, ? anti-TNF, &amp; anti-CD20) <span class="sm">(<i class="calibre6">Semin Arthritis Rheum</i> 2014;43:613)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">CV</b></p></td>
<td class="th1"><p class="tbody">Accel. athero w/ ↑ <b class="calibre7">risk of MI &amp; CV death</b>, AF, pericarditis (effusions in ⅓ of sero ⊕), myocarditis, coronary/systemic vasculitis <span class="sm">(<i class="calibre6">Nat Rev Rheum</i> 2020;16:361)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Nervous</b></p></td>
<td class="th1"><p class="tbody">Nerve entrapment (eg, carpal tunnel), stroke, mononeuritis multiplex, CNS vasculitis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ocular</b></p></td>
<td class="th1"><p class="tbody">Scleritis, episcleritis, keratoconjunctivitis sicca (2° Sjögren’s)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Heme</b></p></td>
<td class="th1"><p class="tbody">Anemia of chronic disease, neutropenia (Felty’s syndrome: 1%, typically long- standing RA + splenomegaly; large granular lymphocyte leukemia: bone marrow infiltrated w/ lymphocytes ± myeloid hypoplasia), NHL, amyloidosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renal</b></p></td>
<td class="th1"><p class="tbody">Glomerulonephritis (usually mesangial), nephrotic syndrome (2° amyloidosis), nephrotoxicity from RA meds</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Vasculitis</b></p></td>
<td class="th1"><p class="tbody">Small &amp; medium vessels (usually ↑ RF titer, long-standing RA); pericarditis, ulcers, scleritis, &amp; neuropathy most common</p></td>
</tr>
</tbody>
</table>
<p class="h">Laboratory &amp; radiologic studies</p>
<p class="noindent1">• <b class="calibre7">RF</b> (IgM/IgA/IgG anti-IgGAb) ⊕ in ~70%; also seen in other rheumatic diseases (SLE, Sjögren’s), cryoglobulinemia, infection (SBE, hepatitis, TB), ~5% of healthy pop.</p>
<p class="noindent1">• <b class="calibre7">Anti-CCP</b> (Ab to cyclic citrullinated peptide): ⊕ in ~70% of Pts w/ RA, similar Se, but more Sp (&gt;90%) than RF particularly for early RA <span class="r1">(</span><span class="r2">Arth Rheum</span> <span class="r1">2009;61:1472)</span>; a/w increased joint damage and low remission rates</p>
<p class="noindent1">• ~20% are seronegative (RF <i class="calibre6">and</i> anti-CCP negative)</p>
<p class="noindent1">• ↑ ESR/CRP but nl in ~30%; ⊕ ANA in ~40%; ↑ globulin during periods of active disease</p>
<p class="noindent1">• Radiographs of hands and wrists: periarticular osteopenia, bone erosions, joint subluxation</p>
<p class="noindent1">• Increasing use of MSK U/S to diagnose synovitis, tenosynovitis, and erosive disease</p>
<p class="h">ACR/EULAR classification criteria <span class="r1">(</span><span class="r2">Arth Rheum</span> <span class="r1">2010;62:2569)</span></p>
<p class="noindent1">• Used in clinical research, but not in clinical practice</p>
<p class="noindent1">• Relevant for Pts with ≥1 joint with synovitis not better explained by another disease</p>
<p class="noindent1">• Likelihood of RA ↑ w/ higher # (espec. ≥4) of small joints involved, ⊕ RF or anti-CCP (espec. high titer), ↑ ESR or CRP, and duration ≥6 wk</p>
<p class="h">Management <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:2328 &amp; 2338;</span> <span class="r2">JAMA</span><span class="r1"> 2018;320:1360)</span></p>
<p class="noindent1">• Early dx and Rx (esp DMARD) w/ frequent follow-up and escalation of Rx as needed with <b class="calibre7">goal to achieve clinical remission</b> or low disease activity</p>
<p class="noindent1">• ↓ time to remission ≈ ↑ length of sustained remission <span class="r1">(</span><span class="r2">Arthritis Res Ther</span> <span class="r1">2010;12:R97)</span></p>
<p class="noindent1">• Sero ⊕ (eg, RF or anti-CCP) a/w aggressive joint disease &amp; extraarticular disease</p>
<p class="noindent1">• At dx, start <i class="calibre6">both</i> rapid-acting agent (to acutely ↓ inflammation) and <b class="calibre7">D</b>isease<b class="calibre7">-M</b>odifying <b class="calibre7">A</b>nti<b class="calibre7">- R</b>heumatic <b class="calibre7">D</b>rug <b class="calibre7">(DMARD)</b> (typically take 1–3 mo to have max effect)</p>
<p class="noindent1"><a id="page_8-4" class="calibre4"></a>• <i class="calibre6">Rapid-acting drugs:</i></p>
<p class="noindent2"><b class="calibre7">NSAIDs</b> or COX-2 inhibitors: ↑ CV risk, GI adverse events, AKI; consider starting w/ PPI</p>
<p class="noindent2"><b class="calibre7">glucocorticoids</b>: low dose (&lt;20 mg/d oral) or joint injection</p>
<p class="noindent2">NSAIDs + glucocorticoids: ↑↑ GI events; give PPI and minimize long-term concurrent use</p>
<p class="noindent1">• <i class="calibre6">DMARDs (see RA therapeutics below):</i></p>
<p class="noindent2"><b class="calibre7">Methotrexate</b> (1<sup class="calibre19">st</sup> line unless CKD, hepatitis, EtOH, or lung disease), alternatives include sulfasalazine (SSZ) or leflunomide; consider HCQ if mild disease</p>
<p class="noindent2">If inadequate response after 3 mo (despite DMARD dose escalation) consider:</p>
<p class="noindent3"><b class="calibre7">combination Rx</b> w/ other DMARDs (eg, “triple therapy” w/ MTX, SSZ, and HCQ) <i class="calibre6">or</i></p>
<p class="noindent3"><b class="calibre7">adding biologic</b> (anti-TNF typically 1<sup class="calibre19">st</sup> line unless contraindication)</p>
<p class="noindent3">MTX/SSZ/HCQ non-inferior to etanercept/MTX <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:307)</span></p>
<p class="noindent3">JAKi: if fail biologics vs. initial DMARD, but ↑ serious side effect risk over abatacept or TNFi (see below) <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;391:2503 &amp; 2513;</span> <span class="r2">NEJM</span> <span class="r1">2020;383:1511;</span> <span class="r2">NEJM</span> <span class="r1">2022;386:316)</span></p>
<p class="noindent1">• Given a/w CV morbidity/mortality, try to ↓ risk w/ lifestyle mgmt, lipid &amp; DM screening</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">RA Therapeutics</b> <span class="sm">(<i class="calibre6">Arth Care Res</i> 2021;73:924)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Class</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Drug</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Side Effects</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Traditional DMARDs</b></p></td>
<td class="th1"><p class="tbodyh">Methotrexate (MTX)</p>
<p class="tbodyh">Leflunomide</p>
<p class="tbodyh">Sulfasalazine (SSZ)</p></td>
<td class="th1"><p class="tbodyh">MTX: GI distress, stomatitis, ILD, myelosuppression, hepatotoxicity</p>
<p class="tbodyh">Supplement MTX ± SSZ w/ folate</p>
<p class="tbodyh">✓ <i class="calibre6">G6PD prior to SSZ</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Biologic DMARDs</b></p>
<p class="tbodyh">(all anti-TNF ≈ efficacy; if inadequate resp to anti- TNF try non-TNF)</p></td>
<td class="th1"><p class="tbodyh">Anti-TNF: etanercept, infliximab, adali- mumab, certolizumab, golimumab</p>
<p class="tbodyh">CTLA4-Ig: abatacept</p>
<p class="tbodyh">Anti-IL-6R Ab: tocilizumab (studied as mono-Rx w/o MTX); sarilumab</p>
<p class="tbodyh">Anti-CD20: rituximab</p>
<p class="tbodyh">Anti-IL-1R: anakinra</p>
<p class="tbodyh"><b class="calibre7"><i class="calibre6">Never use 2 biologics together</i></b></p></td>
<td class="th1"><p class="tbodyh">↑ risk bacterial/fungal/viral infxn</p>
<p class="tbodyh">✓ TB, Hep B/C before starting</p>
<p class="tbodyh">Immunize against Zoster + Pneumococcus</p>
<p class="tbodyh">Anti-TNF: ? risk for CHF &amp; CNS demyelinating disease</p>
<p class="tbodyh">Anti-IL-6R: risk of GI perf.</p>
<p class="tbodyh">Rituximab: infusion reaction</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Other</b></p></td>
<td class="th1"><p class="tbodyh">Hydroxychloroquine (HCQ)</p>
<p class="tbodyh">JAKi: tofacitinib, baricitinib; upadacitinib (JAK1 selective)</p>
<p class="tbodyh">Rare: cyclosporine, azathioprine, gold</p></td>
<td class="th1"><p class="tbodyh">HCQ: retinopathy, rash</p>
<p class="tbodyh">JAKi: infxn, ↑ LFTs, HTN, VTE, CV events, malignancy, death</p>
<p class="tbodyh">CsA: ↑ Cr, HTN, gum hyperplasia</p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h104" class="calibre8"></a><a href="part0003.html#rh115" class="calibre8">ADULT-ONSET STILL’S DISEASE (AOSD) &amp; RELAPSING POLYCHONDRITIS</a></h2>
<p class="h">Adult-onset Still’s disease <span class="r1">(</span><span class="r2">J Autoimmun</span> <span class="r1">2018;93:24)</span></p>
<p class="noindent1">• <b class="calibre7">Rare autoinflammatory syndrome</b>, &lt;4/million per y incidence; ♂ = ♀ w/ bimodal typical onset 15–25 or 36–46 y; sx evolve over wks to mos</p>
<p class="noindent1">• Dx if 5 criteria are present &amp; ≥2 major; exclude infxn, malig, other rheumatic, drug rxn</p>
<p class="noindent2"><b class="calibre7">Major:</b> fever ≥39°C for ≥1 wk (usually daily or twice daily high-spiking fever); arthralgias/ arthritis ≥2 wk; Still’s rash (qv); ↑ WBC w/ 80% PMN</p>
<p class="noindent2"><b class="calibre7">Minor:</b> sore throat; LAN; HSM; ↑ AST/ALT/LDH; negative ANA &amp; RF</p>
<p class="noindent1">• Still’s rash (&gt;85%): nonpruritic macular or maculopapular salmon-colored rash; usually trunk or extremities; may be precipitated by trauma (Koebner phenomenon), warm water</p>
<p class="noindent1">• Plain films: soft tissue swelling (<i class="calibre6">early</i>) → cartilage loss, erosions, carpal ankylosis (<i class="calibre6">late</i>)</p>
<p class="noindent1">• Treatment: NSAIDs; steroids; steroid-sparing (MTX, <b class="calibre7">anakinra</b>, anti-TNF, <b class="calibre7">tocilizumab</b>)</p>
<p class="noindent1">• Variable clinical course: 20% w/ long-term remission; 30% remit-relapse; ~50% chronic (esp. arthritis); ↑ risk of macrophage activation syndrome (life threatening)</p>
<p class="h">Relapsing polychondritis <span class="r1">(</span><span class="r2">Rheumatology</span> <span class="r1">2018;57:1525)</span></p>
<p class="noindent1">• Inflammatory destruction of cartilaginous structures; typical onset age 40–60, ♂=♀, &lt;1/million per y incidence</p>
<p class="noindent1">• Subacute onset of <b class="calibre7">red</b>, <b class="calibre7">painful</b>, and <b class="calibre7">swollen cartilage;</b> ultimately atrophic &amp; deformed</p>
<p class="noindent1">• Multiple sites of cartilaginous inflammation: bilateral auricular chondritis, nonerosive inflammatory arthritis, nasal chondritis, laryngeal or tracheal chondritis, valvulopathy. Ocular inflammation and cochlear/vestibular dysfxn also common.</p>
<p class="noindent1">• 40% of cases a/w immunologic disorder (eg, RA, SLE, vasc., Sjögren’s), cancer or MDS (including VEXAS; <span class="r2">NEJM</span> <span class="r1">2020;383:2628</span>)</p>
<p class="noindent1">• Labs: ↑ ESR &amp; CRP, leukocytosis, eosinophilia, anemia of chronic inflammation</p>
<p class="noindent1">• Bx (not req for dx): proteoglycan depletion, perichondrial inflammation and replacement with granulation tissue and fibrosis; immunofluorescence with Ig and C3 deposits</p>
<p class="noindent1">• Screen for pulm (PFTs, CXR/CT, ± bronch) and cardiac (ECG, TTE) involvement</p>
<p class="noindent1">• Rx guided by disease activity/severity: steroids 1st line; NSAIDs/dapsone for arthralgias, mild disease; MTX, AZA, or biologics steroid-sparing; cyclophosph if organ-threatening</p>
<h2 class="ct"><a id="h105" class="calibre8"></a><a id="page_8-5" class="calibre8"></a><a href="part0003.html#rh116" class="calibre8">CRYSTAL DEPOSITION ARTHRITIDES</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Comparison of Gout and Pseudogout</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Gout</b> <span class="sm">(<i class="calibre6">Rheumatology</i> 2018;58:27)</span></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Pseudogout</b> <span class="sm">(<i class="calibre6">NEJM</i> 2016;374:2575)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Acute clinical</b></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">S</i>udden onset painful <i class="calibre6">mono- articular</i> arthritis (classically <b class="calibre7">podagra</b> [MTP of great toe]) or bursitis; frequently nocturnal</p>
<p class="tbodyh">May be <i class="calibre6">polyarticular</i> in subseq flares</p>
<p class="tbodyh">Can mimic cellulitis (esp in foot)</p></td>
<td class="th1"><p class="tbodyh">Mono- or asymmetric oligoarthritis (esp knees, wrists, and MCP joints); rare axial involvement (eg, crowned dens syndrome)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Chronic clinical</b></p></td>
<td class="th1"><p class="tbodyh">Solid crystal deposition (<b class="calibre7">tophus</b>) in joints (esp. toes, fingers, wrists, knees) &amp; tissue (esp. olecranon bursa, pinna, Achilles)</p></td>
<td class="th1"><p class="tbodyh">“Pseudo-RA” w/ polyarticular arthritis w/ morning stiffness or “Pseudo-OA”</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Assoc. conditions</b></p></td>
<td class="th1"><p class="tbodyh">Metabolic syndrome; CKD; CHF</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">3 H’s:</b> Hyper-PTH, Hypo-Mg, Hemochromatosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Crystal</b></p></td>
<td class="th1"><p class="tbodyh">Monosodium urate (MSU)</p></td>
<td class="th1"><p class="tbodyh">Calcium pyrophosphate dihydrate</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Polarized microscopy<sup class="calibre27"><a id="fn173-s1" class="calibre8"></a><a href="part0014.html#rfn173-s1" class="calibre8">*</a></sup></b></p></td>
<td class="th1"><p class="tbodyh">Needle-shaped, <b class="calibre7">negatively birefringent</b></p></td>
<td class="th1"><p class="tbodyh">Rhomboid-shaped, weakly <b class="calibre7">positively birefringent</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Radio- graphic findings</b></p></td>
<td class="th1"><p class="tbodyh">Early = nonspecific tissue swelling</p>
<p class="tbodyh">Late = tophus, joint erosions w/ overhanging edges</p>
<p class="tbodyh">“Double contour sign” on MSK US</p>
<p class="tbodyh">DECT: UrA vs. Ca deposits</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Chondrocalcinosis:</b> linear densities within articular cartilage; often found in menisci, fibrocartilage of wrist, hands, symphysis pubis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Other</b></p></td>
<td class="th1"><p class="tbodyh">a/w uric acid stones; urate nephropathy</p></td>
<td class="th1"><p class="tbodyh">✓ Ca, Mg, Fe, ferritin, TIBC, UrA, PTH in young or severe cases</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn173-s1" class="calibre8"></a><a href="part0014.html#fn173-s1" class="calibre8">*</a></sup>Crystals should be intracellular; infection can coexist with acute attacks, ∴ always ✓ Gram stain &amp; Cx</p>
<p class="h1cr">G<small class="calibre31">OUT</small></p>
<p class="h">Definition &amp; epidemiology <span class="r1">(</span><span class="r2">Rheumatology</span><span class="r1"> 2018;58:27;</span> <span class="r2">Lancet</span><span class="r1"> 2021;397:1843)</span></p>
<p class="noindent1">• Humans lack enzyme (uricase) to metabolize urate (end-product of purine metabolism)</p>
<p class="noindent1">• MSU crystal deposition promotes inflammation in joints and peri-articular tissue;</p>
<p class="noindent1">• Prev &gt;1/30 American adults, ♂ &gt;♀; peak incidence 5<sup class="calibre19">th</sup> decade; most common inflamm arthritis in ♂ over 30 y; <i class="calibre6">rare</i> in premenopausal ♀ (estrogens ↑ renal urate excretion)</p>
<p class="h">Etiologies</p>
<p class="noindent1">• UrA underexcretion (85–90%): meds (eg, diuretics); idiopathic; ↓ renal function; obesity</p>
<p class="noindent1">• Uric acid (UrA) overproduction (10–15%): ↑ meat, seafood, EtOH, psoriasis, idiopathic, myelo- and lymphoproliferative disease, chronic hemolytic anemia, cytotoxic drugs, rare inherited enzyme defic, genetic variants <span class="r1">(</span><span class="r2">Nature Rev Rheumatol</span> <span class="r1">2018;14:341)</span></p>
<p class="h">Diagnosis</p>
<p class="noindent1">• ↑<b class="calibre7"> UrA is not diagnostic;</b> 25% of measurements nl during flare; ± ↑ WBC &amp; ESR</p>
<p class="noindent1">• <b class="calibre7">Arthrocentesis is gold standard:</b> intracellular negatively birefringent needle-shaped MSU crystal. U/S w/ double-contour sign or dual-energy CT can aid non-invasive dx.</p>
<p class="noindent1">• 2015 ACR/EULAR Classification Criteria <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2015;74:1789)</span> used 1° in research</p>
<p class="h">Acute treatment <span class="r1">(</span><span class="r2">Arthritis Care Res</span> <span class="r1">2020;72:744)</span></p>
<p class="noindent1">• Colchinine, NSAIDs, &amp; steroids all 1<sup class="calibre19">st</sup>-line; choice guided by side effect profile/comorbidities. IL-1i <span class="r1">(</span><span class="r2">J Rheum</span> <span class="r1">2019;46:1345)</span> or ACTH if these contraindicated. Start Rx ASAP; continue until acute flare resolves; consider combo Rx if severe; rest/ice; self-limited w/in 3–21+ d w/o Rx.</p>
<p class="noindent1">• Continue urate-lowering therapy during attack if already taking</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Acute Treatment for Gout</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Drug</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Initial Dose</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">NSAIDs</b> (nonsel or COX-2 inhib)</p></td>
<td class="th1"><p class="tbodyc">Full anti-inflammatory dose → tapering</p></td>
<td class="th1"><p class="tbodyh">Gastritis &amp; GIB risk. Avoid in CKD &amp; CVD.</p>
<p class="tbodyh">≈ efficacy among NSAIDs.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Colchicine</b> (PO; IV no longer available in U.S.)</p></td>
<td class="th1"><p class="tbodyc">1.2 mg then 0.6 mg 1 h later → 0.6 mg bid</p></td>
<td class="th1"><p class="tbodyh">N/V/diarrhea (w/ ↑ dose), marrow suppression, myopathy, neuropathy. ↓ dose in CKD (however, not nephrotoxic).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Corticosteroids</b> (PO, IA, IV, IM)</p></td>
<td class="th1"><p class="tbodyc">eg, prednisone 0.5 mg/kg/d × 5–10 d ± taper</p></td>
<td class="th1"><p class="tbodyh">Rule out joint infection 1<sup class="calibre27">st</sup>.</p>
<p class="tbodyh">Corticosteroid injection if &lt;3 joints.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">ACTH</b> (IM)</p></td>
<td class="th1"><p class="tbodyc">eg, 100 IU IM ×1–2 doses</p></td>
<td class="th1"><p class="tbodyh">↑ cost, ↓ s/e, limited data <span class="sm">(<i class="calibre6">Semin Arthritis Rheum</i> 2014;43:648)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IL-</b>1 <b class="calibre7">inhibitors</b></p>
<p class="tbodyc"><span class="sm">(<i class="calibre6">J Rheumatol</i> 2019;46:1345)</span></p></td>
<td class="th1"><p class="tbodyc">anakinra (100 mg SC qd × 3 d); canakinumab (150 mg SC × 1)</p></td>
<td class="th1"><p class="tbodyh">↑↑ cost; anakinra a/w injection site pain</p>
<p class="tbodyh">Canakinumab approved in EU <span class="sm">(<i class="calibre6">Ann Rheum Dis</i> 2012;71:1839; <i class="calibre6">Arth Rheum</i> 2010;62:3064)</span></p></td>
</tr>
</tbody>
</table>
<p class="h"><a id="page_8-6" class="calibre4"></a>Chronic treatment <span class="r1">(</span><span class="r2">Arthritis Care Res</span> <span class="r1">2020;72:744)</span></p>
<p class="noindent1">• <b class="calibre7">Approach:</b> if ≥2 attacks/y, polyarticular attack, tophus, joint erosions, GFR &lt;60, or urolithiasis → start urate-lowering therapy + pharmacologic Ppx to ↓ risk of acute attacks</p>
<p class="noindent1">• <b class="calibre7">Urate-lowering therapy (ULT):</b> goal UrA &lt;6 mg/dL; when starting ULT, always give with pharm Ppx as below; <i class="calibre6">do NOT d/c during acute attack or due to AKI</i></p>
<p class="noindent1">• <b class="calibre7">Pharmacologic prophylaxis:</b> continue 6 mos w/ above Rx or longer if frequent attacks:</p>
<p class="noindent2">low-dose <b class="calibre7">colchicine</b> (~50% ↓ risk of acute flare; <span class="r2">J Rheum</span> <span class="r1">2004;31:2429</span>), <b class="calibre7">NSAIDs</b> (less evidence; <span class="r2">Ann Rheum Dis</span> <span class="r1">2006;65:1312</span>), low-dose <b class="calibre7">steroids</b>, <b class="calibre7">IL-1 inhibitors</b></p>
<p class="noindent1">• <b class="calibre7">Lifestyle</b> Δs: ↓ intake of meat, EtOH, &amp; seafood, ↑ low-fat dairy, wt loss, avoid dehydration</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Urate-Lowering Therapy (Chronic Treatment for Gout)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Drug (route)</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Mechanism</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Allopurinol</b> (PO)</p></td>
<td class="th1"><p class="tbodyc">Xanthine oxidase</p>
<p class="tbodyc">inhibitor</p></td>
<td class="th1"><p class="tbodyh">1<sup class="calibre27">st</sup> line; adjust starting dose in CKD; titrate ↑ q2–5wk;</p>
<p class="tbodyh">a/w rash, hypersensitivity syndrome (see below), BM suppression <b class="calibre7">(avoid w/ AZA/6-MP)</b>, diarrhea, N/V, hepatitis; monitor CBC, LFT’s; <i class="calibre6">not nephrotoxic</i></p>
<p class="tbodyh">max dose = 800 mg/d</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Febuxostat</b> (PO)</p></td>
<td class="th1"><p class="tbodyc">Nonpurine xanthine oxidase inhib</p></td>
<td class="th1"><p class="tbodyh">2<sup class="calibre27">nd</sup> line; use if allopurinol intolerant;</p>
<p class="tbodyh">a/w ↑ LFT, rash, arthralgias, N/V;</p>
<p class="tbodyh"><b class="calibre7">avoid w/ AZA/6-MP</b> (BM suppress);</p>
<p class="tbodyh">start 40 mg, max dose = 120 mg/d</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pegloticase</b> (IV)</p></td>
<td class="th1"><p class="tbodyc">Recombinant uricase</p></td>
<td class="th1"><p class="tbodyh">For refractory tophaceous gout; infusion reactions (including anaphylaxis); Ab formation may limit use <span class="sm">(<i class="calibre6">JAMA</i> 2011;306:711)</span>; <b class="calibre7">avoid w/ G6PD deficiency</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Probenecid</b> (PO)</p></td>
<td class="th1"><p class="tbodyc">Uricosuric</p></td>
<td class="th1"><p class="tbodyh">Rarely used; risk of urolithiasis</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">Allopurinol hypersensitivity syndrome:</b> 10–25% mortality; incidence ~5/1000. ↓ risk w/ <i class="calibre6">starting</i> dose 100 mg/d if eGFR &gt;40 or 50 mg/d if eGFR ≤40. Titrate by 100 mg/d (eGFR &gt;40) or 50 mg/d (eGFR ≤40) q2–5 wk until UrA &lt;6 mg/dL (dose can be &gt;300 mg/d even in CKD). A/w<i class="calibre6"> HLA-B5801</i>, esp. Han Chinese, Koreans, Thai; screen in these high-risk populations prior to initiating <span class="r1">(</span><span class="r2">Arthritis Care Res</span> <span class="r1">2020;72:744;</span> <span class="r2">JAMA Intern Med</span> <span class="r1">2015;175:1550)</span><i class="calibre6">.</i></p>
<p class="h1cr">C<small class="calibre31">ALCIUM</small> P<small class="calibre31">YROPHOSPHATE</small> D<small class="calibre31">IHYDRATE</small> (CPPD) D<small class="calibre31">EPOSITION</small> D<small class="calibre31">ISEASE</small>/P<small class="calibre31">SEUDOGOUT</small></p>
<p class="h">Definition <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2016;374:2575)</span></p>
<p class="noindent1">• Deposition of CPPD crystals w/in tendons, ligaments, articular capsules, synovium, cartilage; frequently asymptomatic</p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">Nat Rev Rheumatol</span> <span class="r1">2018;14:592)</span></p>
<p class="noindent1">• Most cases <b class="calibre7"><i class="calibre6">idiopathic</i>;</b> consider further metabolic eval in young (&lt;50 y) and florid forms</p>
<p class="noindent1">• Metabolic (<i class="calibre6">3 H’s</i>): hemochromatosis; hyperparathyroidism; hypomagnesemia (esp. in Gitelman’s or Bartter’s syndromes)</p>
<p class="noindent1">• Joint trauma (incl. previous surgery); intra-articular hyaluronate can precipitate attacks</p>
<p class="noindent1">• Familial chondrocalcinosis (autosomal dominant disorder); early-onset, polyarticular dis.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Chondrocalcinosis:</b> calcification of cartilage, resulting from CPPD crystal deposition in articular cartilage, fibrocartilage, or menisci</p>
<p class="noindent2">↑ incidence w/ age; can be asymptomatic; chondrocalcinosis in 20% &gt;60 y at autopsy</p>
<p class="noindent1">• <b class="calibre7">Pseudogout:</b> acute CPPD crystal-induced mono- or asymmetric oligoarticular arthritis, <i class="calibre6">indistinguishable from gout except through synovial fluid exam for crystals</i></p>
<p class="noindent2">location: <b class="calibre7">knees</b>, <b class="calibre7">wrists</b>, and MCP joints; rarely, axial (eg, crowned dens syndrome due to CPPD deposition at C1–C2)</p>
<p class="noindent2">precipitants: surgery, trauma, or severe illness</p>
<p class="noindent1">• Chronic forms: “pseudo-RA” and pyrophosphate arthropathy (resembles OA, can involve axial skeleton)</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Arthrocentesis is gold standard: <b class="calibre7">rhomboid shaped, weakly <i class="calibre6">positively</i> birefringent crystals</b> (yellow <i class="calibre6">perpendicular</i> &amp; blue <i class="calibre6">parallel</i> to axis on polarizer; see table above)</p>
<p class="noindent1">• Radiographs: see table above</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2016;374:2575)</span></p>
<p class="noindent1">• Asymptomatic chondrocalcinosis requires no treatment</p>
<p class="noindent1">• Acute therapy for pseudogout: no RCTs, extrapolated from practice in gout; ∴ same as for gout, though colchicine not as effective</p>
<p class="noindent1">• If associated metabolic disease, Rx of underlying disorder <i class="calibre6">may</i> improve arthritis sx</p>
<p class="noindent1">• Low-dose daily colchicine or NSAID may be effective for prophylaxis or chronic arthropathy</p>
<h2 class="ct"><a id="h106" class="calibre8"></a><a id="page_8-7" class="calibre8"></a><a href="part0003.html#rh117" class="calibre8">SERONEGATIVE SPONDYLOARTHRITIS</a></h2>
<p class="h">Definition and classification system <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2016;374:2563)</span></p>
<p class="noindent1">• Spondyloarthritis (SpA): group of inflammatory disorders that share common clinical manifestations: inflammatory spine disease, peripheral arthritis, enthesitis (see below), and extra-articular manifestations (primarily ocular and skin disease)</p>
<p class="noindent1">• Seronegative = absence of autoantibodies</p>
<p class="noindent1">• Subtypes: ankylosing spondylitis (AS), psoriatic (PsA), reactive (ReA), IBD-assoc, juvenille SpA, and undifferentiated. Distinguished by <i class="calibre6">axial</i> vs. <i class="calibre6">peripheral</i> predominant involvement.</p>
<p class="h">Epidemiology &amp; pathogenesis <span class="r1">(</span><span class="r2">Nat Rev Rheumatol</span> <span class="r1">2015;11:110)</span></p>
<p class="noindent1">• Prevalence 1/200 to 1/50 worldwide; AS and non-radiographic axial SpA most common</p>
<p class="noindent1">• HLA-B27 accounts for ~30% of attributable genetic risk but not required for diagnosis</p>
<p class="noindent1">• Environmental factors likely critical for disease, esp reactive arthritis (ie, infection)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Spondyloarthritis (SpA) Epidemiology and Key Presentation Features</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Disease</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Epidemiology</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Key Features</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ankylosing spondylitis (AS)</p></td>
<td class="th1"><p class="tbody">♂:♀ = 3:1; onset in teens to mid-20s (rare after 40 y)</p></td>
<td class="th1"><p class="tbody">Progressive limitation of spinal motion, a.m. stiffness, buttock pain, “bamboo spine,” ⊕ Schober test</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Psoriatic arthritis (PsA)</p></td>
<td class="th1"><p class="tbody">♂ = ♀; peak incidence 45–54 y; seen in 20–30% of Pts w/ psoriasis</p></td>
<td class="th1"><p class="tbody">In 13–17% arthritis precedes skin findings by yrs; does not correlate with psoriasis activity; a/w HIV</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Reactive arthritis (ReA)</p></td>
<td class="th1"><p class="tbody">♂ &gt;&gt; ♀; 20–40 y; 10–30 d after</p>
<p class="tbody"><b class="calibre7">GI or GU infxn</b><sup class="calibre27"><a id="fn176-s1" class="calibre8"></a><a href="part0014.html#rfn176-s1" class="calibre8">*</a></sup> in genetically susceptible host</p></td>
<td class="th1"><p class="tbody">Arthritis, urethritis, and conjunctivitis.</p>
<p class="tbody">Most resolve w/in 12 mo.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">IBD- associated</p>
<p class="tbody">arthritis</p></td>
<td class="th1"><p class="tbody">♂ = ♀; seen in 20% of IBD Pts; Crohn’s &gt;UC</p></td>
<td class="th1"><p class="tbody">Type I &lt;5 joints: correlates w/ IBD activ.</p>
<p class="tbody">Type II &gt;5 joints or axial disease: does not correlate w/ IBD activity</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn176-s1" class="calibre8"></a><a href="part0014.html#fn176-s1" class="calibre8">*</a></sup>GU: Chlamydia, Ureaplasma urealyticum; GI: Shigella, Salmonella, Yersinia, Campylobacter, <i class="calibre6">C. diff</i>.</p>
<p class="h">Major clinical manifestations <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2017;390:73)</span></p>
<p class="noindent1">• <b class="calibre7">Inflammatory back pain:</b> SI joints (<b class="calibre7">sacroiliitis</b>), apophyseal joints of spine</p>
<p class="noindent2">characterized by <b class="calibre7">IPAIN</b> (<span class="underline">I</span>nsidious onset, <span class="underline">P</span>ain at night, <span class="underline">A</span>ge of onset &lt;40 y, <span class="underline">I</span>mproves w/ exercise/hot water, <span class="underline">N</span>o improvement w/ rest), a.m. stiffness, <i class="calibre6">responsive to NSAIDs</i></p>
<p class="noindent1">• <b class="calibre7">Peripheral arthritis:</b> typically asymmetric, oligoarticular, large joints, lower &gt;upper limbs; however, can be symmetric &amp; polyarticular (thus, mimic RA), espec. in psoriatic arthritis</p>
<p class="noindent1">• <b class="calibre7">Enthesitis:</b> inflammation at site of tendon/ligament insertion into bone, esp Achilles, plantar fascia (calcaneal insertion), pre-patellar, elbow epicondyles</p>
<p class="noindent1">• <b class="calibre7">Rigidity of spine:</b> bamboo spine by X-ray, ankylosis due to progressive growth of bony spurs that bridge intervertebral disc</p>
<p class="noindent1">• <b class="calibre7">Dactylitis:</b> “sausage digit,” inflammation of entire digit (joint + tenosynovial inflamm)</p>
<p class="noindent1">• <b class="calibre7">Uveitis:</b> anterior uveitis <i class="calibre6">most common extra-articular manifestation</i> in seronegative SpA<i class="calibre6">;</i> usually unilateral and p/w pain, red eye, blurry vision, photophobia</p>
<p class="imaget"><img src="../images/00102.jpeg" alt="" class="calibre5"/></p>
<p class="h"><a id="page_8-8" class="calibre4"></a>Clinical assessment <span class="r1">(</span><span class="r2">Nat Rev Rheumatol</span> <span class="r1">2021;17:109)</span></p>
<p class="noindent1">• <b class="calibre7">Seronegative:</b> rheumatoid factor and other autoantibodies usually ⊖; ± ↑ ESR/CRP</p>
<p class="noindent1">• <b class="calibre7">HLA-B27:</b> nonspecific, b/c common in general population (6–8%); most useful when high clinical suspicion but nl imaging; ⊕ 90% of Pts w/ AS, but only 20–80% in other SpA</p>
<p class="noindent1">• <b class="calibre7">Axial disease physical exam</b></p>
<p class="noindent2"><i class="calibre6">The following are not specific PEx findings but useful in monitoring disease during Rx:</i></p>
<p class="noindent2">Lumbar flexion deformity assessed by <b class="calibre7">modified Schober’s test</b> (⊕ if &lt;5 cm ↑ in distance between a point 5 cm below the lumbosacral jxn and another point 10 cm above, when going from standing to maximum forward flexion)</p>
<p class="noindent2">T-spine mobility (extension) and kyphosis severity measured by <b class="calibre7">occiput-to-wall distance</b> (although occiput-to-wall distance also increased in osteoporotic kyphosis)</p>
<p class="noindent1">• <b class="calibre7">Infectious evaluation for reactive arthritis</b> (⊖ studies do not r/o)</p>
<p class="noindent2"><b class="calibre7">GU:</b> U/A, PCR of urine and/or genital swab for <i class="calibre6">Chlamydia;</i> urethritis usually due to <i class="calibre6">Chlamydia</i> infxn preceding arthritis, but can also see sterile urethritis post dysentery</p>
<p class="noindent2"><b class="calibre7">GI:</b> stool Cx, <i class="calibre6">C. diff</i> toxin. Consider HIV in workup for reactive or psoriatic arthritis.</p>
<p class="noindent1">• <b class="calibre7">Radiology</b></p>
<p class="noindent2">MRI preferred for <i class="calibre6">early</i> detection of inflammation (sacroiliitis)</p>
<p class="noindent2">Plain films detect late structural changes (SI erosions/sclerosis)</p>
<p class="noindent3">Calcification of spinal ligaments w/ bridging symm syndesmophytes (“bamboo spine”)</p>
<p class="noindent3">Squaring and generalized demineralization of vertebral bodies (“shiny corners”)</p>
<p class="h">Descriptions of skin manifestations</p>
<p class="noindent1">• <b class="calibre7">Psoriasis:</b> erythematous plaques with sharply defined margins often w/ thick silvery scale</p>
<p class="noindent1">• <b class="calibre7">Circinate balanitis:</b> shallow, painless ulcers of glans penis and urethral meatus</p>
<p class="noindent1">• <b class="calibre7">Keratoderma blennorrhagica:</b> hyperkeratosis of palms/soles, scrotum, trunk, scalp</p>
<p class="noindent1">• <b class="calibre7">Erythema nodosum:</b> red tender nodules in subcutan. fat (panniculitis), typically on shins Ddx includes idiopathic, infxn, sarcoid, drug rxn, vasculitis, IBD, lymphoma</p>
<p class="noindent1">• <b class="calibre7">Pyoderma gangrenosum:</b> neutrophilic dermatosis → painful ulcers w/ violaceous border Ddx incl. idiopathic, IBD, RA, heme and solid malignancies, MGUS, MDS, polycyth. vera</p>
<p class="h">Psoriatic arthritis subtypes <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2018;391:2273 &amp; 2285;</span> <span class="r2">Nat Rev Dis Primers</span> <span class="r1">2021;7:59)</span></p>
<p class="noindent1">• <b class="calibre7">Mono/oligoarticular</b> (large or DIP joint, dactylitic digit): most common initial manifestation</p>
<p class="noindent1">• <b class="calibre7">Polyarthritis</b> (small joints of the hands/feet, wrists, ankles, knees, elbows): indistinguishable from RA, but often asymmetric</p>
<p class="noindent1">• <b class="calibre7">Arthritis mutilans:</b> severe destructive arthritis with bone resorption, esp. hands</p>
<p class="noindent1">• <b class="calibre7">Axial disease:</b> unilateral/asymmetric sacroiliitis</p>
<p class="noindent1">• <b class="calibre7">DIP-limited:</b> good correlation with nail pitting and onycholysis</p>
<p class="h">Treatment approach <span class="r1">(</span><span class="r2">Arthritis Care Res</span> <span class="r1">2019;71:2 &amp; 2019;71:1285;</span> <span class="r2">NEJM</span><span class="r1"> 2021;385:628)</span></p>
<p class="noindent1">• Untreated disease may lead to irreversible structural damage and associated ↓ function</p>
<p class="noindent1">• Early physiotherapy beneficial</p>
<p class="noindent1">• Tight control of inflammation may improve outcomes (eg, in PsA; <span class="r2">Lancet</span> <span class="r1">2015;386:2489</span>)</p>
<p class="noindent1">• <b class="calibre7">NSAIDs:</b> 1<sup class="calibre19">st</sup> line; rapidly ↓ stiffness and pain; prolonged, continuous administration may modify disease course but associated w/ GI and CV toxicity <span class="r1">(</span><span class="r2">Cochrane Database Syst Rev</span> <span class="r1">2015;17:CD010952)</span>; may exacerbate IBD</p>
<p class="noindent1">• <b class="calibre7">Intra-articular corticosteroids</b> in mono- or oligoarthritis; limited role for systemic steroids, esp. for axial disease</p>
<p class="noindent1">• <b class="calibre7">Conventional DMARDs</b> (eg, MTX, SSZ, leflunomide): no efficacy for axial disease or enthesitis; may have role in peripheral arthritis, uveitis, and extra-articular manifestations</p>
<p class="noindent1">• <b class="calibre7">Anti-TNFs:</b> effective for both axial and peripheral SpA, improves function and may slow progression of structural changes; adalimumab or infliximab preferred if eyes involved</p>
<p class="noindent1">• <b class="calibre7">Anti-IL17A</b> (secukinumab, ixekizumab): for both AS and axial and peripheral PsA <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:1329 &amp; 2534;</span> <span class="r2">Lancet</span> <span class="r1">2015;386:1137)</span></p>
<p class="noindent1">• <b class="calibre7">Anti-IL12/23</b> (ustekinumab) and anti-IL23 (guselkumab) for both axial &amp; peripheral PsA <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2020;395:1115)</span> but not axial SpA <span class="r1">(</span><span class="r2">Arthritis Rheumatol</span> <span class="r1">2019;71:258)</span></p>
<p class="noindent1">• <b class="calibre7">PDE-4 inhibitor</b> (apremilast): effective in PsA refractory to conventional DMARD or as first-line <span class="r1">(</span><span class="r2">Rheumatology</span> <span class="r1">2018;7:1253)</span>; a/w GI side effects and wt loss</p>
<p class="noindent1">• <b class="calibre7">JAK inhibitor:</b> for conventional DMARD- or anti-TNF-resistant peripheral and/or axial SpA <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:1525 &amp; 1537; 2021;384:1227)</span></p>
<p class="noindent1">• <b class="calibre7">Other:</b></p>
<p class="noindent2">Abx indicated in ReA if active GU infxn but not typically needed for uncomplicated enteric infx. Can consider prolonged abx for refractory <i class="calibre6">Chlamydia</i> ReA <span class="r1">(</span><span class="r2">Arthritis Rheum</span> <span class="r1">2010;62:1298)</span>, but controversial.</p>
<p class="noindent2">Involve ophtho if suspect eyes affected (may need steroid drops or intravitreal injection)</p>
<p class="noindent2">Treat underlying IBD when appropriate</p>
<h2 class="ct"><a id="h107" class="calibre8"></a><a id="page_8-9" class="calibre8"></a><a href="part0003.html#rh118" class="calibre8">INFECTIOUS ARTHRITIS &amp; BURSITIS</a></h2>
<p class="h1cr">E<small class="calibre31">TIOLOGIES</small> &amp; D<small class="calibre31">IAGNOSIS</small> <small class="calibre31">OF</small> I<small class="calibre31">NFECTIOUS</small> A<small class="calibre31">RTHRITIS</small></p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">Curr Rheumatol Rep</span> <span class="r1">2013;15:332)</span></p>
<p class="noindent1">• <b class="calibre7">Bacterial</b> (nongonococcal): early diagnosis and treatment essential</p>
<p class="noindent1">• <b class="calibre7">Gonococcal</b> (<i class="calibre6">N. gonorrhea</i>): consider in sexually active young adults</p>
<p class="noindent1">• Viral: parvovirus, HCV, HBV, acute HIV, Chikungunya; mainly polyarticular, may mimic RA</p>
<p class="noindent1">• Mycobacterial: monoarticular or axial (Pott’s disease)</p>
<p class="noindent1">• Fungal: <i class="calibre6">Candida</i> (esp. prosthetic joints), coccidiomycosis (valley fever), histoplasmosis</p>
<p class="noindent1">• Other: Lyme, <i class="calibre6">Mycoplasma</i>, <i class="calibre6">Salmonella</i>, Brucellosis, <i class="calibre6">T. whipplei</i></p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2007;297:1478)</span></p>
<p class="noindent1">• H&amp;P w/ poor sensitivity and specificity for septic arthritis</p>
<p class="noindent1">• <b class="calibre7">Arthrocentesis in acute onset inflammatory monoarthritis</b> to r/o septic arthritis; if possible, obtain fluid sample prior to starting antibiotics</p>
<p class="noindent1">• Do not tap through overlying infected area to prevent introducing infxn into joint space</p>
<p class="noindent1">• ✓ Fluid cell count w/ diff, Gram stain, bacterial culture, crystal analysis;<b class="calibre7"> WBC</b> &gt;<b class="calibre7">50k</b></p>
<p class="noindent2"><b class="calibre7">w/ PMN predominance</b> suspicious for bact. infxn; <i class="calibre6">crystals do not r/o septic arthritis!</i></p>
<p class="h1cr">B<small class="calibre31">ACTERIAL</small> (N<small class="calibre31">ONGONOCOCCAL</small>) A<small class="calibre31">RTHRITIS</small></p>
<p class="h">Epidemiology &amp; risk factors <span class="r1">(</span><span class="r2">Infect Dis Clin North Am</span> <span class="r1">2017;31:203)</span></p>
<p class="noindent1">• 1/50,000 incidence per year</p>
<p class="noindent1">• <b class="calibre7">Immunocompromised host:</b> DM, EtOH use, HIV, age &gt;80, SLE, cancer, steroid use, etc.</p>
<p class="noindent1">• <b class="calibre7">Damaged joints:</b> RA, OA, gout, trauma, prior surgery/prosthetic, prior arthrocentesis (rare)</p>
<p class="noindent1">• <b class="calibre7">Bacterial seeding:</b> bacteremia especially secondary to IVDU or endocarditis; direct inoculation or spread from contiguous focus (eg, cellulitis, septic bursitis, osteomyelitis)</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2007;297:1478;</span> <span class="r2">Lancet</span><span class="r1"> 2010;375:846)</span></p>
<p class="noindent1">• Acute onset <b class="calibre7">monoarticular arthritis</b> (&gt;80%) w/ pain (Se 85%), swelling (Se 78%), warmth</p>
<p class="noindent1">• Location: <b class="calibre7">knee</b> (most common), hip, wrist, shoulder, ankle. In IVDU, tends to involve other areas including axial joints (eg, SI, symphysis pubis, sternoclavicular, manubrial joints).</p>
<p class="noindent1">• <b class="calibre7">Constit. sx:</b> fevers (Se 57%), rigors (Se 19%), sweats (Se 27%), malaise, myalgias</p>
<p class="noindent1">• Infection can track from initial site to form fistulae, abscesses, or osteomyelitis</p>
<p class="noindent1">• <i class="calibre6">Septic bursitis must be differentiated from septic arthritis (intra-articular infection)</i></p>
<p class="h">Additional diagnostic studies <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2007;297:1478)</span></p>
<p class="noindent1">• <b class="calibre7">Synovial fluid: WBC usually</b> &gt;<b class="calibre7">50k</b> (Se 62%, Sp 92%) but can be &lt;10k, &gt;<b class="calibre7">90% polys;</b> Gram stain ⊕ in ~75% of <i class="calibre6">Staph</i>, ~50% of GNR; Cx ⊕ in &gt;90%; synovial bx most sens.</p>
<p class="noindent1">• <b class="calibre7">Leukocytosis</b> (Se 90%, Sp 36%); <b class="calibre7">elevated ESR/CRP</b> (Se &gt;90%)</p>
<p class="noindent1">• <b class="calibre7">Blood cultures</b> ⊕ in &gt;50% of cases, ~80% when more than 1 joint involved</p>
<p class="noindent1">• X-rays of joints should be obtained but usually normal until after ~2 wk of infection when may see bony erosions, joint space narrowing, osteomyelitis, and periostitis</p>
<p class="noindent1">• <b class="calibre7">CT &amp; MRI</b> useful esp. for suspected hip infection or epidural abscess</p>
<p class="h">Treatment for native joints <span class="r1">(</span><span class="r2">IDCNA</span><span class="r1"> 2017;31:203)</span></p>
<p class="noindent1">• Prompt empiric antibiotics guided by Gram stain after surgical drainage. If Gram stain ⊖, empiric Rx w/ vancomycin; add anti-pseudomonal agent if IVDU or immunocompromised.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre12"/>
<col class="calibre12"/>
<col class="calibre34"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Common Microbes (by Gram stain)</b></p></td>
<td class="th"><p class="tbodyc"><b class="calibre7">Population</b></p></td>
<td class="th"><p class="tbodyc"><b class="calibre7">Initial Antibiotic Regimen</b> (tailor based on Gram stain, cx, clin course)</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbody"><b class="calibre7">GPC clusters</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">S. aureus</i></p>
<p class="tbody">(most common)</p></td>
<td class="th1"><p class="tbody">Normal joints</p>
<p class="tbody">Prosthetic joints</p>
<p class="tbody">Damaged joints</p></td>
<td class="tb" rowspan="2"><p class="tbody">Vancomycin.</p>
<p class="tbody">Can later Δ to antistaphylococcal penicillin or cefazolin based on sensitivities.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">S. epidermidis</i></p></td>
<td class="th1"><p class="tbody">Prosthetic joints</p>
<p class="tbody">Postprocedure</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GPC chains</b></p></td>
<td class="th1"><p class="tbody">Streptococci</p></td>
<td class="th1"><p class="tbody">Healthy adults</p>
<p class="tbody">Splenic dysfunction</p></td>
<td class="th1"><p class="tbody">PCN-G or ampicillin</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbody"><b class="calibre7">GN</b></p></td>
<td class="th1"><p class="tbody">Diplococci:</p>
<p class="tbody"><i class="calibre6">N. gonorrhea</i></p></td>
<td class="th1"><p class="tbody">Sexually active young adults</p></td>
<td class="th1"><p class="tbody">Ceftriaxone or cefotaxime</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Rods: <i class="calibre6">E. coli</i>,</p>
<p class="tbody"><i class="calibre6">Pseudomonas</i>,</p>
<p class="tbody"><i class="calibre6">Serratia</i></p></td>
<td class="th1"><p class="tbody">IVDU, GI infection</p>
<p class="tbody">immunosupp, trauma</p>
<p class="tbody">elderly</p></td>
<td class="th1"><p class="tbody">Cefepime or piperacillin/tazobactam + antipseudomonal aminoglycoside in IVDU</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">IV antibiotics</b> × ≥2 wk followed by oral antibiotics; varies by clinical course &amp; microbiology</p>
<p class="noindent1">• Joint must be <b class="calibre7">drained</b>, often serially w/ arthroscopy (larger joints, initial Rx) or arthrocentesis. Serial synovial fluid analyses should demonstrate ↓ in WBC and sterility.</p>
<p class="noindent1">• 10–15% mortality (up to 50% w/ polyarticular); depends on virulence, time to Rx, host</p>
<p class="h"><a id="page_8-10" class="calibre4"></a>Prosthetic joint infections <span class="r1">(</span><span class="r2">Infect Dis Clin North Am</span> <span class="r1">2012;26:29;</span> <span class="r2">CID</span> <span class="r1">2013;56:e1)</span></p>
<p class="noindent1">• ↑ risk in first 2 y s/p procedure; rate generally low (0.5–2.4%); risk factors include obesity, RA, immunocompromised state, steroids, &amp; superficial surgical site infxn</p>
<p class="noindent1">• Staphylococci (coag negative &amp; <i class="calibre6">S. aureus</i>) in &gt;50%; polymicrobial in 10–20%</p>
<p class="noindent1">• Early (&lt;3 mo s/p surgery) or delayed (3–24 mo) onset of sx from microbe typically acquired during implantation; early w/ virulent (eg, MRSA) and delayed w/ less virulent organisms (eg, <i class="calibre6">P. acnes</i>, coag negative <i class="calibre6">Staph</i>) &amp; more indolent presentation</p>
<p class="noindent1">• Late (&gt;24 mo) onset typically related to secondary hematogenous seeding</p>
<p class="noindent1">• Diagnosis requires arthrocentesis; ESR &amp; CRP (CRP Se 73–91%, Sp 81– 86%; <span class="r2">NEJM</span> <span class="r1">2009;361:787</span>) can be helpful</p>
<p class="noindent1">• Requires prolonged abx (initial empiric regimen: vanc + 3<sup class="calibre19">rd</sup>/4<sup class="calibre19">th</sup> gen cephalosporin) for 6 wks <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:1991)</span> &amp; 2-stage joint replacement (retention a/w ~40% failure; <span class="r2">CID</span> <span class="r1">2013;56:182</span>) or life-long suppressive abx. <i class="calibre6">Consult ID &amp; orthopedics.</i></p>
<p class="h1cr">D<small class="calibre31">ISSEMINATED</small> G<small class="calibre31">ONOCOCCAL</small> I<small class="calibre31">NFECTION</small> (DGI)</p>
<p class="h">Epidemiology <span class="r1">(</span><span class="r2">Infect Dis Clin North Am</span> <span class="r1">2005;19:853)</span></p>
<p class="noindent1">• <i class="calibre6">N. gonorrhea;</i> most frequent type of infectious arthritis in sexually active young adults</p>
<p class="noindent1">• <b class="calibre7">Normal host</b> as well as Pts w/ deficiencies of terminal components of complement</p>
<p class="noindent1">• ♀:♂ = 4:1 historically, but now ↑ in ♂. Occurs in &lt;3% of <i class="calibre6">N. gonorrhea</i> infxn; ↑ incidence w/ menses, pregnancy, postpartum, SLE; ↑ incidence in MSM.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Preceded by <b class="calibre7">mucosal infection</b> (eg, cervix, urethra, anus, or pharynx) that is often asx</p>
<p class="noindent1">• Two distinct syndromes, although Pts can have both:</p>
<p class="noindent2"><b class="calibre7">Joint-localized:</b> purulent arthritis (40%), usually 1–2 joints (knees &gt;wrists &gt;ankles)</p>
<p class="noindent2"><b class="calibre7">Arthritis-dermatitis syndrome:</b> triad of <b class="calibre7">polyarthralgias, tenosynovitis, skin lesions</b></p>
<p class="noindent2">1) <i class="calibre6">polyarthralgias</i>: migratory joint pain, can affect small or large joints</p>
<p class="noindent2">2) <i class="calibre6">tenosynovitis</i>: pain/inflammation of tendon and its sheath in wrists, fingers, ankles, toes</p>
<p class="noindent2">3) <i class="calibre6">skin lesions</i>: gunmetal gray pustules with erythematous base on extremities &amp; trunk</p>
<p class="noindent1">• Rare complications: Fitz-Hugh-Curtis syndrome (perihepatitis), pericarditis, meningitis, myocarditis, osteomyelitis from direct extension of joint-localized infection</p>
<p class="h">Additional diagnostic studies</p>
<p class="noindent1">• Synovial fluid: <b class="calibre7">WBC</b> &gt;<b class="calibre7">50k</b> (but can be &lt;10k), <b class="calibre7">poly predominant</b></p>
<p class="noindent2">Gram stain ⊕ in ~25%; culture ⊕ in up to 50% if done w/ Thayer-Martin media</p>
<p class="noindent1">• Blood culture: more likely ⊕ in arthritis-dermatitis syndrome; rarely in joint-localized disease</p>
<p class="noindent1">• Gram stain and culture of skin lesions occasionally ⊕</p>
<p class="noindent1">• Cervical, urethral, pharyngeal, rectal PCR or cx on Thayer-Martin media; ✓ <i class="calibre6">Chlamydia</i></p>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">Ceftriaxone</b> ×<b class="calibre7"> 7–14 d w/ empiric doxycycline</b> ×<b class="calibre7"> 7 d</b> for <i class="calibre6">Chlamydia</i> if co-infection has not been excluded (see STI)</p>
<p class="noindent1">• Joint arthroscopy/lavage may be required for purulent arthritis; rarely &gt;1 time</p>
<p class="h1cr">O<small class="calibre31">LECRANON</small> &amp; P<small class="calibre31">REPATELLAR</small> B<small class="calibre31">URSITIS</small></p>
<p class="h">Epidemiology &amp; risk factors <span class="r1">(</span><span class="r2">Joint Bone Spine</span> <span class="r1">2019;86:583)</span></p>
<p class="noindent1">• &gt;150 bursae in the body; 2 most commonly infected are <b class="calibre7">olecranon</b> and <b class="calibre7">prepatellar</b></p>
<p class="noindent1">• Most commonly (esp. superficial bursae) due to direct trauma, percutaneous inoculation, or contiguous spread from adjacent infection (eg, cellulitis)</p>
<p class="noindent1">• Other risk factors: recurrent noninfectious inflammation (eg, gout, RA), diabetes</p>
<p class="noindent1">• <i class="calibre6">S. aureus</i> (80%) most common, followed by streptococci</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Physical exam: discrete bursal swelling, erythema, maximal tenderness at center of bursa with preserved joint range of motion</p>
<p class="noindent1">• Aspirate bursa if concern for infxn, ✓ cell count, Gram stain, bacterial cx, crystals</p>
<p class="noindent2"><b class="calibre7">WBC</b> &gt;<b class="calibre7">20k w/ poly predominance</b> suspicious for bacterial infection, but lower counts very common (crystals do <i class="calibre6">not</i> rule out septic bursitis!)</p>
<p class="noindent1">• Assess for adjacent joint effusion, which can also be septic</p>
<p class="noindent1">• Do <i class="calibre6">not</i> tap through infected skin to avoid introducing infxn into bursa</p>
<p class="h">Initial therapy</p>
<p class="noindent1">• Prompt empiric coverage for staphylococci and streptococci: PO abx acceptable for mild presentation; <b class="calibre7">vancomycin</b> if ill appearing; broaden spectrum based on risk factors</p>
<p class="noindent1">• Modify antibiotics based on Gram stain, culture results, &amp; clinical course. Duration of Rx is 1–3 wks. <b class="calibre7">Serial aspirations</b> every 1–3 d until sterile or no reaccumulation of fluid.</p>
<p class="noindent1">• Surgery if unable to drain bursa through aspiration, evidence of foreign body or necrosis, recurrent/refractory bursitis w/ concern for infxn of adjacent structures</p>
<h2 class="ct"><a id="h108" class="calibre8"></a><a id="page_8-11" class="calibre8"></a><a href="part0003.html#rh119" class="calibre8">CONNECTIVE TISSUE DISEASES</a></h2>
<p class="imaget"><img src="../images/00103.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">Centr, centromere; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cSSc; IM, inflammatory myopathies; RF, rheumatoid factor; Sm, Smith (<i class="calibre6">Primer on the Rheumatic Diseases</i>, 12<sup class="calibre22">th</sup> ed., 2001; <i class="calibre6">Lancet</i> 2013;382:797; <i class="calibre6">J Rheumatol</i> 2015;42:558)</p>
<p class="noindent1">• Only order auto-Ab testing if clinical suspicion for CTD, the presence of auto-Ab without characteristic clinical findings ≠ diagnosis, and auto-Ab do not define a particular CTD</p>
<p class="noindent1">• Overlap syndromes may be reflected by multiple autoantibodies</p>
<p class="h1cr"><span class="r5"><i class="calibre38">see “Systemic Lupus Erythematosus” and “Rheumatoid Arthritis” for those diseases</i></span></p>
<p class="h1cr">S<small class="calibre31">YSTEMIC</small> S<small class="calibre31">CLEROSIS</small> <small class="calibre31">AND</small> S<small class="calibre31">CLERODERMA</small> D<small class="calibre31">ISORDERS</small></p>
<p class="h">Definition &amp; epidemiology <span class="r1">(</span><span class="r2">Best Pract Res Clin Rheumatol</span> <span class="r1">2018;32:223)</span></p>
<p class="noindent1">• <b class="calibre7">Scleroderma</b> refers to the presence of tight, thickened skin</p>
<p class="noindent1">• <b class="calibre7">Localized scleroderma:</b> <i class="calibre6">morphea</i> (plaques of fibrotic skin), <i class="calibre6">linear</i> (fibrotic bands), “<i class="calibre6">en coup de sabre</i>” (linear scleroderma on one side of scalp and forehead ≈ saber scar)</p>
<p class="noindent1">• <b class="calibre7">Systemic sclerosis (SSc)</b> = scleroderma + internal organ involvement. High-mortality.</p>
<p class="noindent2">SSc w/ <i class="calibre6">limited cutaneous disease (lcSSc):</i> formerly CREST syndrome (see below)</p>
<p class="noindent2">SSc w/ <i class="calibre6">diffuse cutaneous disease (dcSSc):</i> often rapidly progressive skin thickening</p>
<p class="noindent2">SSc <i class="calibre6">sine scleroderma</i> (visceral disease without skin involvement, rare)</p>
<p class="noindent1">• Peak onset <b class="calibre7">age 30–50;</b> ♀ &gt;♂ (8:1). Earlier/more severe disease in African Americans</p>
<p class="noindent1">• &lt;6/100,000 annual SSc incidence wordwide; lcSSc incidence ~2× that of dcSSc</p>
<p class="noindent1">• Pathogenesis: unclear. Endothelial injury → ROS/oxidative stress → perivascular inflammation → fibrosis. Cytokines, growth factors, genetics, environ. factors + antibodies (against PDGFR, endo. cells, fibroblasts) may contribute <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;360:1989)</span>.</p>
<p class="h">ACR/EULAR SSc classification criteria <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2013;72:1747)</span></p>
<p class="noindent1">• Sufficient for dx: skin thickening of fingers of both hands extending proximal to MCPs</p>
<p class="noindent1">• Other items considered in criteria: Raynaud’s, SSc-related auto-Ab, pulm hypertension (PHT) and/or ILD, abnormal nailfold capillaries, telangiectasia, fingertip lesions (ulcers, scars), skin thickening distal to MCPs</p>
<p class="noindent1">• <b class="calibre7">Rule out other causes</b> of thickened skin: diabetes (scleredema), scleromyxedema, toxin, hypothyroidism, nephrogenic systemic fibrosis, eosinophilic fasciitis, amyloidosis, GVHD</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Clinical Manifestations of Systemic Sclerosis</b> <span class="sm">(<i class="calibre6">Lancet</i> 2017;390:1685)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Skin</b></p></td>
<td class="th1"><p class="tbodyh">Tightening and thickening of extremities, face, trunk (bx not req for dx)</p>
<p class="tbodyh">“Puffy” hands, carpal tunnel syndrome, sclerodactyly</p>
<p class="tbodyh">Nailfold capillary dilatation &amp; dropout</p>
<p class="tbodyh">Immobile, pinched, “mouse-like” facies and “purse-string” mouth</p>
<p class="tbodyh">Calcinosis cutis (subcutaneous calcification), telangiectasias</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Arteries</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Raynaud’s phenomenon</b> (80%); digital or visceral ischemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renal</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Scleroderma renal crisis (SRC)</b> = abrupt onset of HTN (<i class="calibre6">relative to Pt’s baseline</i>), MAHA. Urine sediment typically bland. Renal bx not required but would show “onion-skin” hypertrophy of arteries &amp; arterioles.</p>
<p class="tbodyh">Affects 5–10%. ACEI effective (see below) but 40% still progress to ESRD and 5y-mortality is 40% <span class="sm">(<i class="calibre6">QJM</i> 2007;100:485)</span>. Risks: dcSSc, early disease (⅔ of cases in 1<sup class="calibre27">st</sup> yr), &gt;15 mg/d prednisone, RNA Pol III Ab.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GI</b> (&gt;80% of Pts)</p></td>
<td class="th1"><p class="tbodyh">GERD and erosive esophagitis, esophageal dysmotility (dysphagia, odynophagia, aspiration), gastric dysmotility, small intestinal dysmotility (malabsorption, bact overgrowth, bloating)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Musculoskel</b></p></td>
<td class="th1"><p class="tbodyh">Arthralgias/arthritis; myositis; joint contractures; tendon friction rubs</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiac</b></p></td>
<td class="th1"><p class="tbodyh">Myocardial fibrosis; pericardial effusion; conduction abnormalities; CAD</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulmonary</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Pulmonary fibrosis</b> (typically develops w/in 4 y); <b class="calibre7">pulmonary arterial hypertension</b> (typically develops after many yrs); #1 cause of mortality</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Endocrine</b></p></td>
<td class="th1"><p class="tbodyh">Amenorrhea and infertility common; thyroid fibrosis ± hypothyroidism</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><a id="page_8-12" class="calibre4"></a><p class="tbodyc"><b class="calibre7">SSc Subgroup Comparison</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Limited (lcSSc)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Diffuse (dcSSc)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">General</b></p></td>
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody">Fatigue, weight loss</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Skin</b></p></td>
<td class="th1"><p class="tbody">Thickening on extremities <i class="calibre6">distal</i> to elbows/knees and <i class="calibre6">face</i> only</p></td>
<td class="th1"><p class="tbody">Thickening of distal <i class="calibre6">and proximal</i> ext, face <i class="calibre6">and trunk</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulmonary</b></p></td>
<td class="th1"><p class="tbody">PAH (rapidly progressive) &gt;fibrosis</p></td>
<td class="th1"><p class="tbody">Fibrosis &gt;PAH</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GI</b></p></td>
<td class="th1"><p class="tbody">Primary biliary cirrhosis</p></td>
<td class="th1"><p class="tbody"> </p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renal</b></p></td>
<td class="th1"><p class="tbody">SRC later in disease course</p></td>
<td class="th1"><p class="tbody">SRC earlier &amp; more common</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiac</b></p></td>
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody">Restrictive cardiomyopathy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Other</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">CREST syndrome</b> = <b class="calibre7">C</b>alcinosis, <b class="calibre7">R</b>aynaud’s, <b class="calibre7">E</b>sophageal dysmotility, <b class="calibre7">S</b>clerodactyly, <b class="calibre7">T</b>elangiectasias</p></td>
<td class="th1"><p class="tbody">Raynaud’s</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Antibodies</b></p></td>
<td class="th1"><p class="tbody">Centromere (10–40%)</p></td>
<td class="th1"><p class="tbody">Scl 70, RNA-Pol III (40%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Prognosis</b></p></td>
<td class="th1"><p class="tbody">Survival &gt;70% at 10 y</p></td>
<td class="th1"><p class="tbody">Survival 40–60% at 10 y</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnostic studies &amp; monitoring <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2017;390:1685)</span></p>
<p class="noindent1">• <b class="calibre7">Autoantibodies:</b> &gt;95% Pts w/ auto-Ab; generally mutually exclusive</p>
<p class="noindent2">⊕<b class="calibre7"> anti-Scl-70</b> (anti-topoisomerase 1): a/w diffuse SSc; ↑ risk pulm fibrosis</p>
<p class="noindent2">⊕<b class="calibre7"> anticentromere:</b> a/w limited SSc; ↑ risk of severe digit ischemia and PHT</p>
<p class="noindent2">⊕<b class="calibre7"> anti-RNA-Pol III:</b> a/w diffuse SSc; ↑ risk renal crisis; a/w cancer</p>
<p class="noindent2">⊕ ANA (&gt;90%), ⊕ RF (30%), ⊕ anti-U1-RNP a/w overlap syndrome</p>
<p class="noindent2">Other: anti-Th/To (a/w limited SSc), U3-RNP (a/w ILD), PmScl (polymyositis-SSc overlap)</p>
<p class="noindent1">• CXCL4 levels reported to correlate w/ degree of fibrosis <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2014;370:433)</span></p>
<p class="noindent1">• At baseline: ✓ BUN/Cr &amp; UA for proteinuria, PFTs (spirometry, lung volumes, D<sub class="calibre10">L</sub>CO), high- res chest CT (if diffuse disease), TTE (RVSP for PHT), RHC if ↑ RVSP or suspect PHT</p>
<p class="noindent1">• Annual PFTs; TTE q1–2y</p>
<p class="noindent1">• Skin bx not routine, but helpful to assess other possible causes for skin thickening</p>
<p class="noindent1">• ↑ risk of malignancy (esp. lung cancer) compared to general population</p>
<p class="noindent1">• Frequent (eg, daily) BP ✓ to monitor for HTN suggestive of scleroderma renal crisis</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2017;76:1327;</span> <span class="r2">Arthritis Rheumatol</span> <span class="r1">2018;70:1820)</span></p>
<p class="noindent1">• <i class="calibre6">Minimize steroid exposure to reduce risk of renal crisis</i></p>
<p class="noindent1">• Interstitial lung disease: tocilizumab <span class="r1">(</span><span class="r2">Lancet Respir Med</span> <span class="r1">2020;8:963)</span>, MMF (↓ toxicity vs. cyclophosphamide; <span class="r2">Lancet Respir Med</span> <span class="r1">2020;8:304</span>); nintedanib (multikinase inhibitor/antifibrotic) a/w ↓ FVC decline <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019; 380:2518)</span>.</p>
<p class="noindent2">PAH: pulmonary vasodilators (see “Pulm Hypertension”); early Rx a/w better outcomes</p>
<p class="noindent1">• Renal crisis: <b class="calibre7">ACEI</b> (not ARB) for Rx, not prophylaxis <span class="r1">(</span><span class="r2">Semin Arthritis Rheum</span> <span class="r1">2015;44:687)</span></p>
<p class="noindent1">• GI: PPI/H2-blockers for GERD; promotility agents &amp; antibx for bacterial overgrowth</p>
<p class="noindent1">• Cardiac: NSAIDs ± colchicine superior to steroids for pericarditis</p>
<p class="noindent1">• Arthritis: acetaminophen, NSAIDs, hydroxychloroquine, MTX</p>
<p class="noindent1">• Myositis: MTX, AZA, steroids</p>
<p class="noindent1">• Skin: PUVA for morphea. Pruritus: emollients, topical/oral steroids. Fibrosis: MTX; MMF? <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2017;76:1207;</span> <span class="r2">Int J Rheum Dis</span> <span class="r1">2017;20:481)</span>. CYC if severe <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;354:2655)</span>.</p>
<p class="noindent1">• Auto-HSCT promising for severe disease <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:35)</span></p>
<p class="h1cr">R<small class="calibre31">AYNAUD</small>’<small class="calibre31">S</small> P<small class="calibre31">HENOMENON</small></p>
<p class="h">Clinical manifestations &amp; diagnosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:556</span><span class="r2">; Nat Rev Rheum</span> <span class="r1">2020;16:208)</span></p>
<p class="noindent1">• Episodic, reversible digital ischemia, triggered by cold temp, or stress, classically: <b class="calibre7">blanching</b> (white, ischemia) → <b class="calibre7">cyanosis</b> (blue, hypoxia) → <b class="calibre7">rubor</b> (red, reperfusion); color Δ usually well demarcated; affects fingers, toes, ears, nose</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Primary vs. Secondary Raynaud’s Phenomenon</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Primary (80–90%)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Secondary (10–20%)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Vessel wall</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Functionally</i> abnl</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Structurally</i> abnl</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Etiologies</b></p></td>
<td class="th1"><p class="tbody">Idiopathic; however, can be exacerbated by comorbid conditions, including HTN, athero, CAD, DM</p></td>
<td class="th1"><p class="tbody">SSc, SLE, PM-DM, MCTD, Sjögren’s, RA</p>
<p class="tbody">Arterial disease (athero, Buerger’s), trauma</p>
<p class="tbody">Heme (cyro, Waldenström’s, APS)</p>
<p class="tbody">Drugs (ergopeptides, estrogens, cocaine)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Epidem.</b></p></td>
<td class="th1"><p class="tbody">20–40 y; ♀ &gt; ♂ (5:1)</p></td>
<td class="th1"><p class="tbody">&gt;35 y</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Clinical</b></p></td>
<td class="th1"><p class="tbody">Mild, <i class="calibre6">symm.</i> episodic attacks.</p>
<p class="tbody"><i class="calibre6">No tissue injury,</i> PVD, or systemic sx<i class="calibre6">; spares thumb.</i></p></td>
<td class="th1"><p class="tbody">Severe, <i class="calibre6">asymm</i>. attacks; <b class="calibre7">tissue ischemia &amp; injury</b> (eg, digital ulcers); can be assoc w/ systemic sx; may affect thumb or prox limbs</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Auto Ab</b></p></td>
<td class="th1"><p class="tbody">⊖ CTD antibodies</p></td>
<td class="th1"><p class="tbody">Depends on etiology, CTD Ab often ⊕</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Nailfold</b></p></td>
<td class="th1"><p class="tbody">Normal capillaroscopy</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Dropout and enlarged or distorted loops</b></p></td>
</tr>
</tbody>
</table>
<p class="h"><a id="page_8-13" class="calibre4"></a>Treatment <span class="r1">(</span><span class="r2">Curr Opin Rheumatol</span> <span class="r1">2021;33:453;</span> <span class="r2">Clin Rheumatol</span> <span class="r1">2019;38:3317)</span></p>
<p class="noindent1">• All: avoid cold, maintain warmth of digits &amp; body; avoid cigarettes, sympathomimetics, caffeine, &amp; trauma; abx for infected ulceration</p>
<p class="noindent1">• <b class="calibre7">Mild–mod: long-acting CCB</b>, topical nitrates, SSRI, ARB, α-blockers, ASA/clopidogrel</p>
<p class="noindent1">• Severe: PDE inhibitors, anti-ET-1 receptor (if ulcers esp. w/ PHT), digital sympathectomy</p>
<p class="noindent1">• Digit-threatening: IV prostaglandins, digital sympathectomy, ± anticoagulation</p>
<p class="h1cr">I<small class="calibre31">NFLAMMATORY</small> M<small class="calibre31">YOPATHIES</small></p>
<p class="h">Definition &amp; epidemiology <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2015;372:1734;</span> <span class="r2">Lancet Neurol</span> <span class="r1">2018;17:816)</span></p>
<p class="noindent1">• All lead to skeletal muscle inflammation &amp; weakness, variable extramuscular involvement</p>
<p class="noindent1">• <b class="calibre7">Polymyositis</b> (PM): incidence &lt;1/million/y; onset typically 40s–50s; ♀ &gt;♂</p>
<p class="noindent1">• <b class="calibre7">Dermatomyositis</b> (DM): similar to PM but w/ skin manifestations; incidence ~1/million/y; also occurs in childhood; <b class="calibre7">malignancy a/w PM</b> (10%) <b class="calibre7">and DM</b> (24%)</p>
<p class="noindent1">• <b class="calibre7">Necrotizing autoimmune myositis</b> (NM): usually adults; risk factors: statin exposure (⊕ anti-HMGCR; <span class="r2">NEJM</span> <span class="r1">2016;374:664</span>), CTD, cancer, rarely viral infection; incidence unclear</p>
<p class="noindent1">• <b class="calibre7">Inclusion body myositis</b> (IBM): age &gt;50; ♂ &gt;♀; incidence ~5/million/y; often <i class="calibre6">misdiagnosed as PM</i></p>
<p class="noindent1">• Ddx: drug-induced toxic myopathy (statins, cocaine, steroids, colchicine); infxn (HIV, EBV, CMV); metabolic (hypothyroid, hypo-K, hypo-Ca); neuromuscular dis. (eg, myasthenia gravis); glycogen storage disease; mitochondrial cytopathy; muscular dystrophy</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Muscle weakness:</b> typically gradual onset (wks to mos) but often accelerated in NM (days to wks) and more insidious (yrs) in IBM; progressive and painless</p>
<p class="noindent2">DM/PM/NM: <b class="calibre7">proximal and symmetric</b><i class="calibre6">;</i> difficulty climbing stairs, arising from chairs, brushing hair; fine motor skills (eg, buttoning) lost late</p>
<p class="noindent2">IBM: weakness may be asymmetric, distal, and involve facial muscles</p>
<p class="noindent1">• <b class="calibre7">Skin findings in dermatomyositis:</b> may precede myositis by mos to yrs</p>
<p class="noindent2"><i class="calibre6">Gottron’s papules</i>: seen in &gt;80% of Pts &amp; pathognomonic; violaceous, often scaly, areas symmetrically over dorsum of PIP and MCP joints, elbows, patellae, medial malleoli</p>
<p class="noindent2"><i class="calibre6">Heliotrope rash</i>: purplish discoloration over upper eyelids ± periorbital edema</p>
<p class="noindent2"><i class="calibre6">Poikiloderma</i>: red or purple rash w/ areas of hyper and hypopigmentation mostly on sun- exposed areas; upper back (shawl sign), neck &amp; chest (V sign), and hips (Holster sign)</p>
<p class="noindent2"><i class="calibre6">Mechanic’s hands</i>: cracking, fissuring radial side of digits and can include pigmentation along palmar crease; a/w antisynthetase syndrome; also seen in PM</p>
<p class="noindent1">• <b class="calibre7">Pulmonary:</b> acute alveolitis, <b class="calibre7">interstitial lung disease</b>; resp muscle weakness; aspiration</p>
<p class="noindent2"><i class="calibre6">Antisynthetase syndrome</i>: acute onset DM or PM w/ <b class="calibre7">rapidly progressive ILD</b>, fever, weight loss, Raynaud’s, mechanic’s hands, arthritis; most commonly <b class="calibre7">anti-Jo-1</b> ⊕</p>
<p class="noindent2"><i class="calibre6">MDA5-assoc. DM:</i> ↑ amyopathic, ↑ rapidly progressive ILD, palmar papules, skin ulcers</p>
<p class="noindent1">• <b class="calibre7">Cardiac:</b> (33%): often asx; conduction abnl; myo/pericarditis; HF uncommon; ↑ CK-MB/Tn</p>
<p class="noindent1">• <b class="calibre7">GI:</b> dysphagia, aspiration</p>
<p class="noindent1">• <b class="calibre7">Polyarthralgias or polyarthritis:</b> usually early, nonerosive; small joints &gt;large joints</p>
<p class="noindent1">• <b class="calibre7">Raynaud’s</b> (30%, DM and overlap CTD) w/ dilatation &amp; dropout of nail bed capillaries</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2017;76:1955)</span></p>
<p class="noindent1">• ↑ <b class="calibre7">CK</b> (rarely &gt;100,000 U/L, can be ↑↑↑ in NM), aldolase, SGOT, LDH; ± ↑ ESR &amp; CRP</p>
<p class="noindent1">• Autoantibodies: ⊕ ANA (&gt;75%)</p>
<p class="noindent2">⊕<b class="calibre7"> anti-Jo-1</b> (25%): most common specific Ab; a/w antisynthetase syndrome</p>
<p class="noindent2">⊕ anti-Mi-2 (DM &gt;PM 15–20%) is a/w disease that responds well to steroids</p>
<p class="noindent2">⊕ anti-SRP is a/w NM, poor Rx response; ⊕ anti-HMGCR in NM a/w statin exposure</p>
<p class="noindent2">Multiple others <span class="r1">(</span><span class="r2">Best Pract Res Clin Rheumatol</span> <span class="r1">2018;32:887)</span>. Often ordered as an Ab panel.</p>
<p class="noindent1">• Consider <b class="calibre7">EMG</b> (↑ spontaneous activity, ↓ amplitude, polyphasic potentials w/ contraction) or <b class="calibre7">MRI</b> (muscle edema, inflammation, atrophy) for evaluation; may guide biopsy</p>
<p class="noindent1">• <b class="calibre7">Pathology and muscle biopsy:</b> all with interstitial mononuclear infiltrates, muscle fiber necrosis, degeneration, &amp; regeneration (required for definitive diagnosis)</p>
<p class="noindent2">PM: CD8 <i class="calibre6">T cell-mediated muscle injury;</i> perivascular and endomysial inflammation surrounds MHC class I-expressing non-necrotic fibers</p>
<p class="noindent2">DM: <i class="calibre6">immune complex deposition in blood vessels</i> with complement activation; <i class="calibre6">perifascicular atrophy</i> w/ interfascicular and perivascular inflam (B &amp; CD4 T cells)</p>
<p class="noindent2">NM: necrotic fibers w/ macrophages</p>
<p class="noindent2">IBM: <i class="calibre6">T cell-mediated injury, vacuole formation;</i> same as PM w/ eosinophilic inclusions and rimmed vacuoles and chronic myopathic changes (variable fiber size)</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Nat Rev Rheum</span> <span class="r1">2018;14:279)</span></p>
<p class="noindent1">• Immunosuppression not effective for IBM. For all others:</p>
<p class="noindent1">• <b class="calibre7">Steroids</b> (prednisone 1 mg/kg); MTX or AZA early if mod/severe or taper fails (2–3 mo)</p>
<p class="noindent1"><a id="page_8-14" class="calibre4"></a>• For resistant (30–40%) or severe disease: AZA/MTX combo, IVIg (NM, DM ± PM), rituximab, MMF, cyclophosphamide (esp. if ILD or vasculitis)</p>
<p class="noindent1">• IVIg w/ pulse steroids acutely for life-threatening esophageal or resp muscle involvement</p>
<p class="noindent1">• ✓<b class="calibre7"> for occult malignancy</b> (esp. if DM); monitor respiratory muscle strength with spirometry</p>
<p class="noindent1">• NM: stop statin; steroids + MTX, RTX, or IVIg</p>
<p class="imaget"><img src="../images/00104.jpeg" alt="" class="calibre5"/></p>
<p class="h1cr">S<small class="calibre31">JÖGREN’S</small> S<small class="calibre31">YNDROME</small> <span class="r3">(</span><span class="r4">NEJM</span><span class="r3"> 2018;378:931)</span></p>
<p class="h">Definition &amp; epidemiology</p>
<p class="noindent1">• Chronic dysfxn of<b class="calibre7"> exocrine glands</b> (eg, salivary/lacrimal) due to lymphoplasmacytic infiltration, extraglandular manifestations common in primary form</p>
<p class="noindent1">• Can be primary or secondary (a/w RA, scleroderma, SLE, PM, hypothyroidism, HIV)</p>
<p class="noindent1">• ~1/1000 prevelance with 9:1 ♀:♂ ratio; typically presents between age 40 &amp; 60</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Dry eyes</b> (keratoconjunctivitis sicca): ↓ tear production; burning, scratchy sensation</p>
<p class="noindent1">• <b class="calibre7">Dry mouth</b> (xerostomia): difficulty speaking/swallowing, <b class="calibre7">dental caries</b>, xerotrachea, thrush</p>
<p class="noindent1">• <b class="calibre7">Parotid gland enlargement:</b> intermittent, painless, typically bilateral</p>
<p class="noindent1">• <b class="calibre7">Vaginal dryness</b> and<b class="calibre7"> dyspareunia</b></p>
<p class="noindent1">• <b class="calibre7">Recurrent nonallergic rhinitis/sinusitis</b> due to upper airway gland involvement</p>
<p class="noindent1">• <b class="calibre7">Extraglandular manifestations:</b> arthritis, interstitial nephritis (40%), type I RTA (20%), cutaneous vasculitis (25%), PNS &gt;CNS neurological disease (20%), ILD, PBC</p>
<p class="noindent1">• ↑ risk of lymphoproliferative disorders (~50× ↑ risk of lymphoma and WM in 1° Sjögren’s)</p>
<p class="noindent1">• Neonatal lupus, including fetal skin rash or heart block (a/w SSA and/or SSB antibodies)</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Autoantibodies: ⊕ ANA (95%), ⊕ RF (75%)</p>
<p class="noindent2">Primary Sjögren’s: ⊕ <b class="calibre7">anti-Ro</b> (anti-SSA, ~50%) ± <b class="calibre7">anti-La</b> (anti-SSB, ~30%)</p>
<p class="noindent1">• <b class="calibre7">Schirmer test:</b> filter paper in palpebral fissures to assess tear production</p>
<p class="noindent1">• <b class="calibre7">Rose-Bengal</b> staining: dye that reveals devitalized epithelium of cornea/conjunctiva</p>
<p class="noindent1">• <b class="calibre7">Ocular staining score:</b> substitute for Rose-Bengal staining to determine degree of keratoconjunctivitis sicca using fluorescein and lissamine green</p>
<p class="noindent1">• <b class="calibre7">Biopsy</b> (minor salivary, labial, lacrimal, or parotid gland): lymphocytic infiltration</p>
<p class="h">Classification criteria <span class="r">(≥4 points 96% Se &amp; 95% Sp;</span> <span class="r2">Arthritis Rheumatol</span> <span class="r1">2017;69:35</span><span class="r">)</span></p>
<p class="noindent1">• 3 points: ⊕ anti-Ro; labial saliv. gland bx w/ lymphocytic sialadenitis &amp; score ≥1 foci/4 mm<sup class="calibre19">2</sup></p>
<p class="noindent1">• 1 point: abnormal ocular staining score ≥5; Schirmer’s test ≤5 mm/5 min; unstimulated salivary flow rate of ≤0.1 mL/min</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2020;79:3)</span></p>
<p class="noindent1">• Ocular: artificial tears, cyclosporine eyedrops, autologous tears</p>
<p class="noindent1">• Oral: sugar-free gum, lemon drops, saliva substitute, hydration, pilocarpine, cevimeline</p>
<p class="noindent1">• Systemic: depends on extraglandular manifest.; NSAIDs, steroids, DMARDs, rituximab</p>
<p class="h1cr">M<small class="calibre31">IXED</small> C<small class="calibre31">ONNECTIVE</small> T<small class="calibre31">ISSUE</small> D<small class="calibre31">ISEASE</small> (MCTD)</p>
<p class="h">Definition <span class="r1">(</span><span class="r2">Best Pract Res Clin Rheumatol</span> <span class="r1">2016;30:95)</span></p>
<p class="noindent1">• Features of<b class="calibre7"> SLE</b>, <b class="calibre7">systemic sclerosis</b>, and/or <b class="calibre7">polymyositis</b> that appear gradually over years and often evolve to a dominant phenotype of SLE or systemic sclerosis</p>
<p class="noindent1">• Different from undifferentiated CTD (UCTD): nonspecific symptoms that fail to meet criteria for any CTD; 30% go on to develop CTD over 3–5 y (usually SLE)</p>
<p class="h">Clinical &amp; laboratory manifestations <span class="r1">(</span><span class="r2">Rheumatology</span> <span class="r1">2018;57:255)</span></p>
<p class="noindent1">• <b class="calibre7">Raynaud’s phenomenon</b> (qv) typical presenting symptom (75–90%)</p>
<p class="noindent1">• Hand edema (“puffy hands”), sclerodactyly, RA-like <b class="calibre7">arthritis</b> w/o erosions, polyarthralgias</p>
<p class="noindent1">• Pulmonary involvement (85%) with <b class="calibre7">pulmonary hypertension</b>, fibrosis</p>
<p class="noindent1">• Pericarditis most frequent cardiovascular manifestation; GI: dysmotility (70%)</p>
<p class="noindent1">• Membranous &amp; mesangial GN common (25%); low risk for renal HTN crisis or severe GN</p>
<p class="noindent1">• ⊕ ANA (&gt;95%); ⊕ RF (50%); requires ⊕ <b class="calibre7">anti-U1-RNP</b> but <i class="calibre6">not</i> specific (seen in ~50% SLE)</p>
<p class="h">Treatment: <span class="r">as per specific rheumatic diseases detailed above</span></p>
<h2 class="ct"><a id="h109" class="calibre8"></a><a id="page_8-15" class="calibre8"></a><a href="part0003.html#rh120" class="calibre8">SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)</a></h2>
<p class="h">Definition and epidemiology <span class="r1">(</span><span class="r2">Nat Rev Rheumatol</span> <span class="r1">2021;17:515)</span></p>
<p class="noindent1">• Multisystem inflammatory autoimmune disease with a broad spectrum of clinical manifestations in association with antinuclear antibody (ANA) production</p>
<p class="noindent1">• Prevalence 5–35/10,000 in U.S.; predominantly affects women 2<sup class="calibre19">nd</sup> to 4<sup class="calibre19">th</sup> decade</p>
<p class="noindent1">• ♀:♂ ratio = 8:1; African Americans affected 2–4× as often as Caucasians</p>
<p class="noindent1">• Complex genetics; some HLA association; rarely C1q &amp; C2 deficiency</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre37"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Classification Criteria</b> <span class="sm">(<i class="calibre6">Ann Rheum Dis</i> 2019;78:1151)</span> for <i class="calibre6">research/classification</i> not dx</p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbodyc">Required criteria: <b class="calibre7">ANA titer</b> ≥1<b class="calibre7">:80</b> AND ≥1<b class="calibre7">0</b> points (at least one clinical):</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbodyc"><b class="calibre7">Clinical domains</b> (points<sup class="calibre27"><a id="fn181-s1" class="calibre8"></a><a href="part0014.html#rfn181-s1" class="calibre8">*</a></sup>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renal</b></p>
<p class="tnl"><span class="tft">•</span> proteinuria &gt;0.5 g/d (4)</p>
<p class="tnl"><span class="tft">•</span> class II or V nephritis (8)</p>
<p class="tnl"><span class="tft">•</span> class III or IV nephritis (10)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Hematologic</b></p>
<p class="tnl"><span class="tft">•</span> leukopenia (3)</p>
<p class="tnl"><span class="tft">•</span> thrombocytopenia (4)</p>
<p class="tnl"><span class="tft">•</span> autoimm. hemolytic anemia (4)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Neuropsychiatric</b></p>
<p class="tnl"><span class="tft">•</span> delirium (2)</p>
<p class="tnl"><span class="tft">•</span> psychosis (3)</p>
<p class="tnl"><span class="tft">•</span> seizure (5)</p></td>
</tr>
<tr class="calibre15">
<td rowspan="2" class="th1"><p class="tbody"><b class="calibre7">Mucutaneous</b></p>
<p class="tnl"><span class="tft">•</span> non-sclarring alopecia (2)</p>
<p class="tnl"><span class="tft">•</span> oral ulcers (2)</p>
<p class="tnl"><span class="tft">•</span> discoid lupus (4); subacute (4) or acute (6) cutaneous lupus</p></td>
<td rowspan="2" class="th1"><p class="tbody"><b class="calibre7">Serosal</b></p>
<p class="tnl"><span class="tft">•</span> pleural/pericardial effusion (5)</p>
<p class="tnl"><span class="tft">•</span> acute pericarditis (6)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Musculoskeletal</b></p>
<p class="tnl"><span class="tft">•</span> joint involvement (6)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Constitutional</b></p>
<p class="tnl"><span class="tft">•</span> fever (2)</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbodyc"><b class="calibre7">Immunology domains</b> (points<sup class="calibre27"><a href="part0014.html#rfn181-s1" class="calibre8">*</a></sup>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Antiphospholipid antibodies</b></p>
<p class="tnl"><span class="tft">•</span> anti-CL, anti-B2GP1, or a lupus anticoagulant (2)</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Complement proteins</b></p>
<p class="tnl"><span class="tft">•</span> low C3 or C4 (3)</p>
<p class="tnl"><span class="tft">•</span> low C3 and C4 (4)</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">SLE-specific Abs</b></p>
<p class="tnl"><span class="tft">•</span> anti-dsDNA or anti- Smith (6)</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn181-s1" class="calibre8"></a><a href="part0014.html#fn181-s1" class="calibre8">*</a></sup>Within each domain, only the highest weighted criterion is counted toward the total score.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre23"/>
<col class="calibre18"/>
<col class="calibre12"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Autoantibodies in SLE</b> <span class="sm">(<i class="calibre6">Nat Rev Rheumatol</i> 2020;16:565)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Auto-Ab</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Frequency (approx)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Clinical Associations</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Timeline</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">ANA</b></p></td>
<td class="th1"><p class="tbody">95–99% if active disease</p>
<p class="tbody">90% if in remission</p>
<p class="tbody">Homogeneous or speckled</p></td>
<td class="th1"><p class="tbody">Any or all of broad spectrum of clinical manifestations</p>
<p class="tbody">Sensitive but not specific</p></td>
<td class="th1" rowspan="2"><p class="tbodyc">May appear yrs before overt disease</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ro</b></p>
<p class="tbody"><b class="calibre7">La</b></p></td>
<td class="th1"><p class="tbody">15–35%</p>
<p class="tbody">⊕ anti-Ro may be seen w/ ⊖ or low titer ANA</p></td>
<td class="th1"><p class="tbody">Sjögren’s/SLE overlap</p>
<p class="tbody">Neonatal lupus; photosens.; subacute cutaneous lupus</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">ds-DNA</b></p></td>
<td class="th1"><p class="tbody">70%; ~95% Sp; titers may parallel dis. activity, esp. renal</p></td>
<td class="th1"><p class="tbody">Lupus nephritis</p>
<p class="tbody">Vasculitis</p></td>
<td class="tb" rowspan="3"><p class="tbodyc">Appears mos before or at dx, but may become ⊕ after dx</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Sm</b></p></td>
<td class="th1"><p class="tbody">30%; very specific for SLE</p></td>
<td class="th1"><p class="tbody">Lupus nephritis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">U</b>1<b class="calibre7">-RNP</b></p></td>
<td class="th1"><p class="tbody">40%</p></td>
<td class="th1"><p class="tbody">MCTD; Raynaud’s;</p>
<p class="tbody">Tend <i class="calibre6">not</i> to have nephritis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Histone</b></p></td>
<td class="th1"><p class="tbody">90% in DLE; 60–80% in SLE</p></td>
<td class="th1"><p class="tbody">Mild arthritis and serositis</p></td>
<td class="th1"><p class="tbodyc">At diagnosis</p></td>
</tr>
</tbody>
</table>
<p class="h">Workup</p>
<p class="noindent1">• Autoantibodies: ANA, if ⊕ → ✓ anti-ds-DNA, anti-Sm, anti-Ro, anti-La, anti-U1-RNP</p>
<p class="noindent1">• CBC, APLA (⊕ in 20–40%; ACL, B2GP1, lupus anticoagulant), total complement, C3 &amp; C4</p>
<p class="noindent1">• Lytes, BUN, Cr, U/A, urine sed, spot microalb:Cr ratio or 24-h urine for CrCl and protein</p>
<p class="noindent1">• If ↓ GFR, active sediment, hematuria, or proteinuria (&gt;0.5 g/dL) → renal bx to guide Rx</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre37"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Treatment</b> <span class="sm">(<i class="calibre6">Ann Rheum Dis.</i> 2019;78:736; <i class="calibre6">Lancet</i> 2019;393:2332; <i class="calibre6">Nat Rev Rheumatol</i> 2019;15:30)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Drug</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Indication</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Adverse Effects</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Hydroxychloroquine (HCQ)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">All Pts b/c</b> ↓ <b class="calibre7">flares</b> <span class="sm">(<i class="calibre6">NEJM</i> 1991;324:150)</span>; monoRx for arthritis, serositis, skin disease</p></td>
<td class="th1"><p class="tbody">Retinal tox (&lt;1%), Stevens- Johnson; myopathy. <i class="calibre6">Not immunosuppressive.</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">NSAIDs</b></p></td>
<td class="th1"><p class="tbody">Arthritis, myalgias, serositis</p></td>
<td class="th1"><p class="tbody">Gastritis, UGIB, renal failure</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Corticosteroids</b></p></td>
<td class="th1"><p class="tbody">Low dose for arthritis, serositis; high-dose (1 mg/kg) ± pulse (1 g × 3 d) for major dis. (eg, renal, CNS, heme). Minimize as able.</p></td>
<td class="th1"><p class="tbody">Adrenal suppression, diabetes, cataracts, osteopenia, avascular necrosis of bone, myopathy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mycophenolate (MMF)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Nephritis</b> (induction/maint);</p>
<p class="tbody">nonrenal refractory to HCQ</p></td>
<td class="th1"><p class="tbody">Cytopenias, ↑ LFTs, diarrhea, teratogen</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cyclophosphamide (CYC)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Severe organ-threatening nephritis or CNS disease</b> (induction, minimize exposure)</p></td>
<td class="th1"><p class="tbody">Cytopenias, infertility/teratogen, myeloprolif. dis., hemorrhagic cystitis, bladder cancer</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Azathioprine (AZA)</b></p></td>
<td class="th1"><p class="tbody">Nephritis (maintenance)</p>
<p class="tbody">Non-renal dis. refractory to HCQ</p></td>
<td class="th1"><p class="tbody">Myelosuppr. (✓TPMT), ↑ LFTs, teratogen, lymphoprolif. dis.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><a id="page_8-16" class="calibre4"></a><p class="tbody"><b class="calibre7">Methotrexate (MTX)</b></p></td>
<td class="th1"><p class="tbody">Arthritis (preferred over MMF/AZA)</p>
<p class="tbody">Skin disease &amp; serositis</p></td>
<td class="th1"><p class="tbody">Myelosuppression, alopecia, hepatotoxicity, stomatitis,</p>
<p class="tbody">pneumonitis, teratogen</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cyclosporine (CsA)</b></p></td>
<td class="th1"><p class="tbody">Renal disease</p></td>
<td class="th1"><p class="tbody">Hyperplastic gums, HTN,</p>
<p class="tbody">hirsutism, CKD, anemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Voclosporin</b> (calcineurin inhibitor <span class="sm"><i class="calibre6">Lancet</i> 2021;397:2070)</span></p></td>
<td class="th1"><p class="tbody">Nephritis (induction). Added to MMF+steroids; ↑ complete renal response w/ ↓ steroid.</p></td>
<td class="th1"><p class="tbody">HTN, ↓ GFR, diarrhea.</p>
<p class="tbody">(Stable PK, ∴ does not require levels like other calcineurin inhibitors)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Belimumab</b></p>
<p class="tbody"><span class="sm">(<i class="calibre6">NEJM</i> 2013;368:1528 &amp; 2020;383:1117)</span></p></td>
<td class="th1"><p class="tbody">Arthritis, serositis, skin disease (esp. if ⊕ ds-DNA or ↓ C3/C4).</p>
<p class="tbody">Nephritis (induction). ↑ renal response when added.</p></td>
<td class="th1"><p class="tbody">B-cell depletion by binding BLyS (less immunosuppressive than RTX)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Rituximab (RTX)</b></p></td>
<td class="th1"><p class="tbody">ITP, AIHA, refractory SLE</p></td>
<td class="th1"><p class="tbody">Infusion reaction / serum sickness, PML, infection</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Baricitinib</b> <span class="sm">(<i class="calibre6">Lancet</i> 2018;392:222)</span></p></td>
<td class="th1"><p class="tbody">Prelim data: 4 mg w/ efficacy in arthritis, skin disease</p></td>
<td class="th1"><p class="tbody">Infections (zoster), ↑ LFTs, cytopenias, dyslipidemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Anifrolumab</b> (anti- IFN receptor)</p></td>
<td class="th1"><p class="tbody">Moderate to severe disease <span class="sm">(<i class="calibre6">NEJM</i> 2020;382:211)</span></p></td>
<td class="th1"><p class="tbody">Infection (PNA, zoster), hypersensitivity reaction</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre37"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Lupus Nephritis – 40% affected</b> <span class="sm">(<i class="calibre6">Nat Rev Rheumatol</i> 2020;16:255)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Class</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Presentation</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Treatment (all benefit from HCQ)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">I: Min. mesangial</p></td>
<td class="th1"><p class="tbody">Normal U/A &amp; eGFR</p></td>
<td class="th1"><p class="tbody">No specific treatment</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">II: Mesangial prolif</p></td>
<td class="th1"><p class="tbody">Micro hematuria/proteinuria</p></td>
<td class="th1"><p class="tbody">No specific treatment ± ACEI</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">III: Focal prolif</p></td>
<td class="th1"><p class="tbody">Hematuria/proteinuria, ± HTN, ↓ GFR, ± nephrotic</p></td>
<td class="th1"><p class="tbody">Induce: MMF <i class="calibre6">or</i> CYC + steroids</p>
<p class="tbody">Maintenance: MMF &gt;AZA</p>
<p class="tbody"><span class="sm">(<i class="calibre6">NEJM</i> 2004;350:971 &amp; 2005;353:2219 &amp; 2011;365:1886)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">IV: Diffuse prolif</p></td>
<td class="th1"><p class="tbody">Hematuria/proteinuria and HTN, ↓ GFR, ± nephrotic</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">V: Membranous</p>
<p class="tbody">(can coexist with class III or IV)</p></td>
<td class="th1"><p class="tbody">Proteinuria, nephrotic</p></td>
<td class="th1"><p class="tbody">ACEI</p>
<p class="tbody">If nephrotic-range proteinuria, induce w/ MMF + steroids</p>
<p class="tbody">Maintenance: MMF superior to AZA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">VI: Adv. Sclerotic</p></td>
<td class="th1"><p class="tbody">ESRD</p></td>
<td class="th1"><p class="tbody">Renal replacement therapy</p></td>
</tr>
</tbody>
</table>
<p class="h">Prognosis <span class="r1">(</span><span class="r2">Nat Rev Rheumatol</span> <span class="r1">2021;17:515)</span></p>
<p class="noindent1">• Overall mortality 2–3× higher than general population, higher in Blacks.</p>
<p class="noindent1">• Leading causes of morbidity/mortality: <b class="calibre7">infection</b>, CV events, <b class="calibre7">renal failure</b> (nephritis remission achieved in &lt;50%; &gt;10% end up w/ ESRD), neurologic events, thrombosis</p>
<p class="h">Drug-induced lupus (DLE) <span class="r1">(</span><span class="r2">Drug Saf</span> <span class="r1">2017;16:1255;</span> <span class="r2">Autoimmun Rev</span> <span class="r1">2018;17:912)</span></p>
<p class="noindent1">• Many drugs: <b class="calibre7">procainamide</b>, <b class="calibre7">hydralazine</b>, penicillamine, minocycline, INH, methyldopa, quinidine, chlorpromazine, diltiazem, <b class="calibre7">anti-TNF</b> (esp. infliximab), interferons</p>
<p class="noindent1">• Abrupt onset; generally mild disease with arthritis, serositis, skin disease; renal dx, malar and discoid rash rare; prevalence ♀:♂ = 1:1</p>
<p class="noindent1">• ⊕ Anti-histone (95%) (may be ⊖ in anti-TNF); ⊖ anti-ds-DNA (often ⊕ in anti-TNF cases, even w/o manifestations of DLE) &amp; ⊖ anti-Sm; normal complement levels</p>
<p class="noindent1">• Usually reversible w/in 4–6 wk after stopping medication</p>
<h2 class="ct"><a id="h110" class="calibre8"></a><a href="part0003.html#rh121" class="calibre8">IGG4-RELATED DISEASE</a></h2>
<p class="h">Definition &amp; etiology <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2012;366:539;</span> <span class="r2">Nat Rev Rheumatol</span> <span class="r1">2020;16:702)</span></p>
<p class="noindent1">• Characterized by tumor-like inflammatory lesions that can affect nearly any organ</p>
<p class="noindent1">• Etiology: ? autoimmune; unclear role of IgG4; may have h/o atopy</p>
<p class="noindent1">• ♂ &gt;♀, mean age ~ 60. Incidence ~1/100,000 per y in Japan, but elsewhere unknown.</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Arthritis Rheumatol</span> <span class="r1">2015;67:2466 &amp; 2020;72:7)</span></p>
<p class="noindent1">• Commonly pancreatitis, aortitis, cholangitis, sialadenitis, thyroiditis, dacroadenitis, orbital myositis ± pseudotumor, retroperitoneal fibrosis, renal and lung involvement</p>
<p class="noindent1">• Insidious progression; multiple lesions may be present synchronously or metachronously</p>
<p class="h">Diagnosis and management <span class="r1">(</span><span class="r2">Lancet Rheumatol</span> <span class="r1">2019;1:e55)</span></p>
<p class="noindent1">• <b class="calibre7">Biopsy</b> w/ specific findings: lymphoplasmacytic infiltrate w/ significant IgG4+ plasma cell infiltrate, storiform fibrosis, obliterative phlebitis</p>
<p class="noindent1">• ↑ serum IgG4 (Se 90%, Sp 60%); may have low C3, C4</p>
<p class="noindent1">• Highly responsive to steroids but relapse common. Efficacy of DMARDs in maintenance remains unclear but B-cell depleting agents appear promising <span class="r1">(</span><span class="r2">Eur J Intern Med</span> <span class="r1">2020;74:92)</span>.</p>
<h2 class="ct"><a id="h111" class="calibre8"></a><a id="page_8-17" class="calibre8"></a><a href="part0003.html#rh122" class="calibre8">VASCULITIS</a></h2>
<p class="h1cr">O<small class="calibre31">VERVIEW</small></p>
<p class="noindent1">• Inflammation w/in blood vessel walls causing end-organ damage often a/w systemic sx; may be primary or secondary (eg, infection, malignancy) in etiology</p>
<p class="noindent1">• Classified by size of <i class="calibre6">predominant</i> vessel affected <span class="r1">(</span><span class="r2">Arthritis Rheum</span> <span class="r1">2013;65:1)</span>; overlap of vessel size affected is common</p>
<p class="noindent1">• Clinical manifestations based on size of vessels involved; constitutional sx (low-grade fever, fatigue, weight loss, myalgias, anorexia) common to all</p>
<p class="imaget"><img src="../images/00105.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">TAK, Takayasu’s arteritis; GCA, giant cell arteritis; PAN, polyarteritis nodosa; ANCA-assoc. is GPA, EGPA, &amp; MPA; IC, immune complex small-vessel vasculitis (eg, IgA, cryoglobulinemia); GN, glomerulonephritis.</p>
<p class="h1cr">L<small class="calibre31">ARGE</small>-V<small class="calibre31">ESSEL</small> V<small class="calibre31">ASCULITIS</small></p>
<p class="h">Takayasu’s arteritis <span class="r">(“pulseless disease”)</span></p>
<p class="noindent1">• <b class="calibre7">Arteritis of aorta and its branches</b> →<b class="calibre7"> stenosis/aneurysm</b> → claudication. Most often <b class="calibre7">subclavian</b> &amp; <b class="calibre7">innominate arteries</b> (&gt;90%); carotid, coronary, renal, or pulm a. (~50%)</p>
<p class="noindent1">• Epidemiology: most common in <b class="calibre7">Asia;</b> ♀:♂ ~9:1 in Japan but lower elsewhere; <b class="calibre7">age</b> &lt;<b class="calibre7">50 y</b>. Prev 8/million in U.S. w/ ~4:1 ♀:♂ <span class="r1">(</span><span class="r2">J Rheumatol</span> <span class="r1">2021;48:952)</span>.</p>
<p class="noindent1">• Clinical manifestations: systemic inflamm with <b class="calibre7">fever</b>, <b class="calibre7">arthralgias</b>, wt loss</p>
<p class="noindent2">Vessel inflamm w/ pain &amp; tenderness, ↓ <b class="calibre7">&amp; unequal pulses/BPs in extremities</b>, <b class="calibre7">bruits</b>, limb claudication, renovascular HTN (&gt;50%), neurogenic syncope, Ao aneurysm ± AI</p>
<p class="noindent2">“Burnt out” or fibrotic period (eg, vascular stenosis)</p>
<p class="noindent1">• Dx studies: ↑ ESR (75%), CRP; <b class="calibre7">arteriography</b> (MRA, CTA) → occlusion, stenosis, irregularity, and aneurysms; carotid U/S Doppler studies; PET-CT; <b class="calibre7">pathology</b> → focal panarteritis, cellular infiltrate with <i class="calibre6">granulomas</i> and giant cells (bx not required for dx)</p>
<p class="noindent1">• Rx: <b class="calibre7">steroids</b> ± MTX, AZA, or anti-TNF; tocilizumab 2<sup class="calibre19">nd</sup> line <span class="r1">(</span><span class="r2">Ann Rheum Dis</span><i class="calibre6">.</i> <span class="r1">2020;79:19)</span>; ASA if critical cerebral stenosis; if surgical/endovascular revasc, preferably done in remission</p>
<p class="noindent1">• Monitoring: MRA, CTA, or PET-CT; ESR/CRP</p>
<p class="h">Giant cell arteritis (GCA) <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2016;315:2442)</span></p>
<p class="noindent1">• <b class="calibre7">Granulomatous arteritis</b> typically involving<b class="calibre7"> aorta/branches</b>; predilection for <b class="calibre7">extracranial branches of carotid a.</b>, particularly temporal a. (thus also called <b class="calibre7">temporal arteritis</b>).</p>
<p class="noindent1">• Epidemiology: 90% &gt;60 y, peak incidence at 70–80 y, extremely rare &lt;50 y; ♀:♂ = 3:1. Prev 2/1000 of those age ≥50 <span class="r1">(</span><span class="r2">Semin Arthritis Rheum</span> <span class="r1">2017;47:253)</span>.</p>
<p class="noindent1">• Clinical manifestations <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:50)</span>: constitutional sx: <b class="calibre7">fevers</b>, fatigue, wt loss</p>
<p class="noindent2"><b class="calibre7">Temporal artery (TA)</b> →<b class="calibre7"> headache, tender TAs</b> and scalp, absent TA pulse</p>
<p class="noindent2">Ophthalmic artery (20%) → optic neuropathy, diplopia, amaurosis fugax, blindness</p>
<p class="noindent2">Facial arteries → <b class="calibre7">jaw claudication</b></p>
<p class="noindent2">Large vessel vasculitis → intermittent claudication of extremities; thoracic aorta aneurysm</p>
<p class="noindent2"><b class="calibre7">Strong association w/ PMR</b>; ~50% of Pts w/ GCA ultimately received PMR diagnosis</p>
<p class="noindent1">• Dx: ↑ <b class="calibre7">ESR</b> (Se 84%, Sp 30%), ↑ CRP (Se 86%, Sp 30%), anemia.</p>
<p class="noindent2"><b class="calibre7">Temporal artery bx</b> (shows vasculitis &amp; granulomas) whenever<i class="calibre6"> GCA suspected</i> (Se ≤85%); consider bilat to ↑ yield (3–7% discordant). If bx ⊖ or suspect aortitis/large vessel involvement: U/S (halo sign) or MRA of temporal/cranial arteries, or CTA, MRA, or PET of aorta/large arteries <span class="r1">(</span><span class="r2">Arthritis Rheumatol</span> <span class="r1">2021;73:1349)</span>. Some advocate imaging upfront to r/o, but requires imaging expertise <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2018;77:636 &amp; 2020;79:19)</span>.</p>
<p class="noindent1">• Rx: <b class="calibre7">steroids</b>: <i class="calibre6">do not await bx/path!</i> Have &gt;2 wks to bx w/o Δ. Pred 40–60 mg/d w/ <i class="calibre6">slow</i> taper; ASA if critical cerebral narrowing; consider IV steroids if vision threatened <span class="r1">(</span><span class="r2">Arthritis Rheumatol</span> <span class="r1">2021;73:1349)</span>. Adding tocilizumab ↑ sustained remission <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:317)</span>.</p>
<p class="noindent1"><a id="page_8-18" class="calibre4"></a>• <b class="calibre7">Polymyalgia rheumatica</b> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:2442;</span> <span class="r2">Lancet</span> <span class="r1">2017;390:1700)</span></p>
<p class="noindent2">Prev 7/1000 of age ≥50. In 50% of GCA Pts; 15% of PMR Pts develop GCA. ♀:♂ ≈ 2.</p>
<p class="noindent2">ESR &gt;40 mm/h (and/or ↑ CRP); <i class="calibre6">bilateral</i> <b class="calibre7"><i class="calibre6">pain &amp; morning stiffness</i></b> (&gt;30 min), involving 2 of 3 areas: neck or torso, shoulders or prox. arms, hips or prox. thighs; nighttime pain; ± subdeltoid bursitis on U/S; exclude other causes of sx (eg, RA); nl CK</p>
<p class="noindent2">Rx: pred 12.5–25 mg/d; if clinical response, initiate slow taper. If not, consider alternate dx or ↑ dose. Consider MTX if at ↑ risk of steroid side effects <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2015;74:1799)</span>.</p>
<p class="noindent1">• Follow clinical status &amp; ESR/CRP; ~⅓relapse over 2 y <span class="r1">(</span><span class="r2">J Rheum</span> <span class="r1">2015;42:1213)</span></p>
<p class="h1cr">M<small class="calibre31">EDIUM</small>-V<small class="calibre31">ESSEL</small> V<small class="calibre31">ASCULITIS</small></p>
<p class="h">Polyarteritis nodosa <span class="r">(“classic” PAN)</span> <span class="r1">(</span><span class="r2">Nat Rev Rheumatol</span> <span class="r1">2017;13:381)</span></p>
<p class="noindent1">• <b class="calibre7">Necrotizing nongranulomatous vasculitis of medium &amp; small arteries</b> (w/in muscular media) w/o glomerulonephritis or capillary involvement (ie, no DAH), not a/w ANCA</p>
<p class="noindent1">• Incidence ~2/million/y; ↑ in HBV-endemic areas; ♂ &gt;♀; av. age ~50; 10% <b class="calibre7">HBV-assoc</b></p>
<p class="noindent1">• Clinical manifestations <span class="r1">(</span><span class="r2">Arth Rheum</span> <span class="r1">2010;62:616)</span>: const. sx (80%): wt loss, <b class="calibre7">fever</b>, fatigue</p>
<p class="noindent2">Neuro (79%): <b class="calibre7">mononeuritis multiplex</b>, peripheral neuropathies, stroke</p>
<p class="noindent2">Musculoskeletal (64%): <b class="calibre7">extremity pain</b>, <b class="calibre7">myalgias</b>, arthralgias, arthritis</p>
<p class="noindent2">Renal (51%): <b class="calibre7">HTN</b>, hematuria, proteinuria, renal failure; <i class="calibre6">glomerulonephritis unusual</i></p>
<p class="noindent2">GI (38%): <b class="calibre7">abd pain</b>, GIB/infarction, cholecystitis; GU (25%): ovarian or testicular pain</p>
<p class="noindent2">Skin (50%): <b class="calibre7">livedo reticularis</b>, purpura, nodules, ulcers, Raynaud’s</p>
<p class="noindent2">Ophthalmic (9%): retinal vasculitis, retinal exudates, conjunctivitis, uveitis</p>
<p class="noindent2">Cardiac (22%): coronary arteritis, cardiomyopathy, pericarditis</p>
<p class="noindent2">Pulmonary: rare; <i class="calibre6">if lung involvement, suspect other vasculitis</i></p>
<p class="noindent1">• Dx <span class="r1">(</span><span class="r2">Arthritis Care Res</span> <span class="r1">2021;73:1061)</span>: ↑ ESR/CRP; r/o ANCA, HBV; ↓ C3/C4 if HBV-assoc.</p>
<p class="noindent2"><b class="calibre7">Angiogram</b> (mesenteric or renal vessels) → <b class="calibre7">microaneurysms</b> &amp; focal vessel narrowing</p>
<p class="noindent2">CTA or MRA may be adequate for dx, but conventional angiogram is most sensitive</p>
<p class="noindent2"><b class="calibre7">Biopsy</b> (nerve, deep-skin, or affected organ) → vasculitis of small and medium a. w/ fibrinoid necrosis <i class="calibre6">w/o granulomas</i></p>
<p class="noindent1">• Rx: based on severity; <b class="calibre7">steroids</b> ± DMARD (MTX, AZA; CYC if severe); antivirals if HBV. Most dis. monophasic so consider stopping DMARD if in steroid-free remission at 18 m.</p>
<p class="h1cr">ANCA-A<small class="calibre31">SSOCIATED</small> S<small class="calibre31">MALL</small>-V<small class="calibre31">ESSEL</small> V<small class="calibre31">ASCULITIS</small></p>
<p class="center"><i class="calibre6">Microvascular vasculitis (eg, capillaries, postcapillary venules, &amp; arterioles)</i></p>
<p class="imaget"><img src="../images/00106.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn184-a" class="calibre8"></a>a</sup>Predominant type, can see either type (<i class="calibre6">NEJM</i> 2012;367:214). <sup class="calibre22"><a id="rfn184-b" class="calibre8"></a>b</sup>GPA is formerly Wegener’s granulomatosis, EGPA is formerly Churg-Strauss. Microscopic polyangiitis (MPA).</p>
<p class="h">Differential diagnosis of ANCA <span class="r1">(</span><span class="r2">Nat Rev Dis Primers</span> <span class="r1">2020;6:71)</span></p>
<p class="noindent1">• <b class="calibre7">anti-PR3:</b> GPA, EGPA, microscopic polyangiitis (rarely), levamisole (contam. in cocaine)</p>
<p class="noindent1">• <b class="calibre7">anti-MPO:</b> microscopic polyangiitis, EGPA, GPA, drug-induced vasculitis, nonvasculitic rheumatic dis., levamisole (contaminant in cocaine)</p>
<p class="noindent1">• <b class="calibre7">Atypical ANCA patterns:</b> drug-induced vasculitis, nonvasculitic rheumatic diseases, ulcerative colitis, primary sclerosing cholangitis, endocarditis, cystic fibrosis</p>
<p class="h">Granulomatosis with polyangiitis <span class="r">(GPA, formerly Wegener’s granulomatosis)</span></p>
<p class="noindent1">• <b class="calibre7">Necrotizing granulomatous systemic vasculitis</b> frequently affecting upper respiratory tract (nose, sinuses) in addition to kidneys, lower resp tract (lungs), and other organs</p>
<p class="noindent1">• Epi: incidence 12/million/y; any age but ↑ in young/middle-aged adults; ♂=♀</p>
<p class="noindent1">• Clinical manifestations</p>
<p class="noindent2">Constitutional: fever, fatigue, malaise, anorexia, <b class="calibre7">weight loss</b></p>
<p class="noindent2"><b class="calibre7">Respiratory</b> (90%): <span class="underline">Upper</span>: <b class="calibre7">recurrent sinusitis</b>, rhinitis, oral/nasal ulcers, <b class="calibre7">nasal crusting</b>, <b class="calibre7">saddle-nose deformity</b>, otitis, hearing loss, subglottic stenosis <span class="underline">Lower</span>: infiltrates, nodules, &amp; hemorrhage → cough, dyspnea, hemoptysis, pleurisy</p>
<p class="noindent2"><b class="calibre7">Renal</b> (80%): <b class="calibre7">RPGN</b>, microscopic hematuria (dysmorphic RBCs and casts)</p>
<p class="noindent2">Skin (50%): palpable purpura, livedo reticularis</p>
<p class="noindent2">Ocular (50%): episcleritis, scleritis, uveitis, orbital granulomas → proptosis, corneal ulcer</p>
<p class="noindent2">Neuro: cranial + peripheral neuropathies, <b class="calibre7">mononeuritis multiplex.</b></p>
<p class="noindent2">Heme: ↑ incidence DVT/PE (20×) when disease active <span class="r1">(</span><span class="r2">Ann Intern Med</span> <span class="r1">2005;142:620)</span></p>
<p class="noindent1"><a id="page_8-19" class="calibre4"></a>• Dx studies: <b class="calibre7">90%</b> ⊕ <b class="calibre7">ANCA</b> (80% PR3, 20% MPO), less Se in limited upper-airway disease</p>
<p class="noindent2">CXR or CT → nodules, infiltrates, cavities; sinus CT → sinusitis ± bone erosions</p>
<p class="noindent2">↑ BUN &amp; Cr, proteinuria, hematuria; sediment w/ RBC casts, dysmorphic RBCs</p>
<p class="noindent2">Biopsy → necrotizing granulomatous inflammation of arterioles, capillaries, veins. Renal bx w/ pauci-immune (minimal immune deposition) necrotizing and crescentic GN.</p>
<p class="noindent1">• Treatment: assess severity w/ BVAS/GPA score <span class="r1">(</span><span class="r2">Arth Rheum Dis</span> <span class="r1">2009;68:1827)</span></p>
<p class="noindent2"><b class="calibre7">Mild disease</b> (no end-organ dysfxn; BVAS 0–3): <b class="calibre7">MTX</b> + <b class="calibre7">steroids</b> <span class="r1">(</span><span class="r2">Arth Rheum</span> <span class="r1">2012;64:3472)</span></p>
<p class="noindent2"><b class="calibre7">Severe disease</b> (end-organ damage incl. pulm hemorrhage, RPGN etc.; BVAS &gt;3):</p>
<p class="noindent2"><i class="calibre6">Induction:</i> [<b class="calibre7">RTX</b> 375 mg/m<sup class="calibre19">2</sup>/wk × 4 wk or 1000 mg on d1 + d15 <i class="calibre6">or</i> <b class="calibre7">CYC</b> 2 mg/kg/d × 3–6 mo or pulse 15 mg/kg q2–3 wk] + <b class="calibre7">steroids</b> 1 g IV × 3 d → ~1 mg/kg/d <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2015;74:1178)</span>. RTX preferred as ↓ toxicity <span class="r1">(</span><span class="r2">Arth Rheum</span> <span class="r1">2021;73:1366)</span>.</p>
<p class="noindent2">Plasma exchange (PLEX) may ↓ risk of ESRD in those most at risk <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:622;</span> <span class="r2">Arth Rheum</span> <span class="r1">2021;73:1366)</span>.</p>
<p class="noindent2">Adding avacopan (oral C5a receptor inhibitor) increases remission rate and allows ↓ steroids <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:599)</span></p>
<p class="noindent2"><i class="calibre6">Maintenance:</i> RTX q6mo superior to AZA or observ. <span class="r1">(</span><span class="r2">Ann Intern Med</span> <span class="r1">2020;173:179)</span></p>
<p class="noindent2"><b class="calibre7">Relapse:</b> mild → steroids ± MTX or AZA; severe → reinduce w/ steroids + RTX or CYC</p>
<p class="noindent2">↑ ANCA w/o clinical evidence of flare should <i class="calibre6">not</i> prompt Δ Rx <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2007;147:611)</span></p>
<p class="h">Microscopic polyangiitis <span class="r">(MPA)</span> <span class="r1">(</span><span class="r2">Rheum Dis Clin North Am</span> <span class="r1">2010;36:545)</span></p>
<p class="noindent1">• Similar to GPA, but <b class="calibre7">w/o ENT/upper airway involvement &amp; nongranulomatous</b></p>
<p class="noindent1">• Epidemiology: incidence 4/million/y. ♂ = ♀; avg onset 50–60 y</p>
<p class="noindent1">• Clinical manifestations</p>
<p class="noindent2">Constitutional, neuro sx similar to GPA</p>
<p class="noindent2"><b class="calibre7">Renal</b> (80–100%): glomerulonephritis</p>
<p class="noindent2"><b class="calibre7">Skin</b> lesions (eg, palpable purpura) in 30–60%</p>
<p class="noindent2"><b class="calibre7">Pulmonary</b> (25–50%): pulmonary capillary alveolitis, pulmonary fibrosis</p>
<p class="noindent1">• Dx studies: <b class="calibre7">70%</b> ⊕ <b class="calibre7">ANCA</b> (almost all anti-MPO)</p>
<p class="noindent2">Biopsy → necrotizing, <b class="calibre7">nongranulomatous</b> inflammation of small vessels, pauci-immune</p>
<p class="noindent2">Urine sediment and CXR findings similar to those seen in GPA</p>
<p class="noindent1">• Treatment: as for GPA <span class="r1">(</span><span class="r2">Arth Rheum</span> <span class="r1">2021;73:1366)</span>; ↓ relapse rate compared to GPA</p>
<p class="h">Eosinophilic granulomatosis with polyangiitis <span class="r">(EGPA, formerly Churg-Strauss)</span></p>
<p class="noindent1">• Similar to GPA w/ more frequent <b class="calibre7">cardiac involvement</b>, a/w <b class="calibre7">asthma</b> and <b class="calibre7">eosinophilia</b></p>
<p class="noindent1">• Epi: rare (incidence 2/million/y); any age (typically 30–40 y); ♂ = ♀; a/w HLA-DRB4</p>
<p class="noindent1">• Clinical manifestations <span class="r1">(</span><span class="r2">Rheumatol</span> <span class="r1">2020;59:iii84)</span></p>
<p class="noindent2">Initial sx: <b class="calibre7">asthma</b>, sinusitis, allergic rhinitis (new asthma in adult raises suspicion)</p>
<p class="noindent2">Eosinophilic infiltrative disease: transient <b class="calibre7">pulm infiltrates</b>, gastroenteritis, or esophagitis</p>
<p class="noindent2">Systemic small-vessel vasculitis: <b class="calibre7">neuropathy</b> (mononeuritis multiplex), renal (glomerulonephritis), skin (palpable purpura, petechial, nodules)</p>
<p class="noindent2"><b class="calibre7">Cardiac:</b> coronary arteritis, myocarditis, CHF, valvular insufficiency <span class="r1">(</span><span class="r2">Medicine</span> <span class="r1">2009;88:236)</span></p>
<p class="noindent1">• Dx studies: 50% ⊕ ANCA (MPO &gt;PR3), <b class="calibre7">eosinophilia</b> (&gt;1500/uL or 10%, often &gt;60%),</p>
<p class="noindent2">biopsy → microgranulomas, fibrinoid necrosis, small artery/vein thromboses w/ eosinophilic infiltrate</p>
<p class="noindent1">• Treatment: high-dose <b class="calibre7">steroids</b> + mepolizumab (anti-IL-5) (if nonsevere) or RTX or CYC (if severe) <span class="r1">(</span><span class="r2">Arth Rheum</span> <span class="r1">2021;73:1366)</span>; mepolizumab for relapse/refractory <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:1921)</span></p>
<p class="h">Renal-limited vasculitis</p>
<p class="noindent1">• Small vessel pauci-immune vasculitis causing RPGN w/o other organ involvement</p>
<p class="noindent1">• Dx studies: 80% ⊕ ANCA (MPO &gt;PR3); biopsy with pauci-immune GN ± granulomas</p>
<p class="noindent1">• Treatment identical to that for GPA/MPA</p>
<p class="h1cr">I<small class="calibre31">MMUNE</small> C<small class="calibre31">OMPLEX</small> (IC)–A<small class="calibre31">SSOCIATED</small> S<small class="calibre31">MALL</small>-V<small class="calibre31">ESSEL</small> V<small class="calibre31">ASCULITIS</small></p>
<p class="h">IgA vasculitis <span class="r">(formerly Henoch-Schönlein purpura [HSP])</span> <span class="r1">(</span><span class="r2">Rheumatol</span> <span class="r1">2019;58:1607)</span></p>
<p class="noindent1">• <b class="calibre7">IgA-mediated</b> small-vessel vasculitis w/ predilection for <b class="calibre7">skin</b>, <b class="calibre7">GI tract</b>, and <b class="calibre7">kidneys</b></p>
<p class="noindent1">• Epidemiology: incidence 140/million/y; ♂ &gt;♀, children &gt;adults, winter &gt;summer</p>
<p class="noindent1">• May develop ~10 d after onset of upper resp infx or after drug exposure</p>
<p class="noindent1">• Clinical manifestations</p>
<p class="noindent2"><b class="calibre7">Palpable purpura</b> on extensor surfaces (lower extremity first) &amp; buttocks</p>
<p class="noindent2"><b class="calibre7">Polyarthralgias</b> (nondeforming) esp. involving hips, knees, &amp; ankles</p>
<p class="noindent2">Colicky <b class="calibre7">abdominal pain</b> ± GIB or intussusception</p>
<p class="noindent2">Nephritis ranging from <b class="calibre7">microscopic hematuria</b> &amp; proteinuria to ESRD</p>
<p class="noindent1">• Dx studies: <b class="calibre7">skin bx w/ immunofluorescence</b> →<b class="calibre7"> leukocytoclastic vasculitis w/ IgA</b></p>
<p class="noindent2">and <b class="calibre7">C3</b> deposition in vessel wall; renal bx → mesangial IgA deposition</p>
<p class="noindent1">• Treatment: often self-limiting over 4 wk; steroids ± DMARDs for renal or severe disease</p>
<p class="h"><a id="page_8-20" class="calibre4"></a>Cryoglobulinemic vasculitis <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2012;379:348;</span> <span class="r2">Nat Rev Dis Primers</span> <span class="r1">2018;4:11)</span></p>
<p class="noindent1">• Cryo<span class="underline">globulins</span>: proteins that <b class="calibre7">precipitate</b> from<i class="calibre6"> serum or plasma</i> <b class="calibre7">on exposure to cold and redissolve on rewarming</b>, characterized by their composition; a/w chronic immune stimulation and/or lymphoproliferation</p>
<p class="noindent1">• Distinguish from <i class="calibre6">cryo<span class="underline">fibrinogenemia</span></i> = proteins (eg, fibrin, fibrinogen) that precipitate only from <i class="calibre6">plasma;</i> found in autoimmune dis, malignancies, infxns; unclear clinical significance</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Types of Cryoglobulinemia</b> <span class="sm">(<i class="calibre6">J Autoimmun</i> 2019;105:102313)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Type I (monoclonal)</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Type II (mixed)</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Type III (mixed)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Frequency</b></p></td>
<td class="th1"><p class="tbodyc">10–15%</p></td>
<td class="th1"><p class="tbodyc">50–60%</p></td>
<td class="th1"><p class="tbodyc">25–30%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cryoglobulin composition</b></p></td>
<td class="th1"><p class="tbodyc"><i class="calibre6">Monoclonal</i> Ig (usually IgM or IgG)</p></td>
<td class="th1"><p class="tbodyc"><i class="calibre6">Monoclonal</i> IgM w/ RF activity + <i class="calibre6">polyclonal</i> IgG</p></td>
<td class="th1"><p class="tbodyc"><i class="calibre6">Polyclonal</i> IgG and IgM</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Common etiologies</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Plasma cell</b></p>
<p class="tbodyc"><b class="calibre7">dyscrasias</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Infection, malignancy</b>, autoimmune syndromes</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Autoimmune synd.,</b> infxn</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Primary manifestations</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Hyperviscosity</b></p>
<p class="tbodyc">± thrombosis → ischemia</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">IC-mediated vasculitis</b>, w/ multiorgan involvement. Can be asx.</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Epidemiology: ~1/100,000, but prevalence varies with HCV rates; ♀ &gt;♂</p>
<p class="noindent1">• Etiologies (idiopathic in ~10%)</p>
<p class="noindent2"><b class="calibre7">Hematologic diseases:</b> multiple myeloma, MGUS, Waldenström’s, chronic lymphocytic leukemia in type I; B-cell lymphomas or solid-organ malignancies in type II</p>
<p class="noindent2">Infxns (types II &amp; III): viral (<b class="calibre7">HCV</b> [&gt;80% RNA ⊕], HBV, HIV, HAV, EBV, CMV), bacterial (endocarditis, strep, etc.), fungal (coccidiomycosis, etc.), parasitic (malaria, amoebiasis)</p>
<p class="noindent2">Autoimmune syndromes (type III &gt;II): <b class="calibre7">Sjögren’s syndrome</b>, SLE, RA, PAN</p>
<p class="noindent2">Renal transplant recipients <span class="r1">(</span><span class="r2">Clin Nephrol</span> <span class="r1">2008;69:239)</span></p>
<p class="noindent1">• Pathophysiology</p>
<p class="noindent2">Type I: cryo precipitation in microcirculation → <b class="calibre7">hyperviscosity</b> &amp; <b class="calibre7">vascular occlusion</b></p>
<p class="noindent2">Types II/III: defective/insufficient immune complex (IC) clearance → IC-mediated inflammation of blood vessels w/ complement activation → <b class="calibre7">vasculitis</b></p>
<p class="noindent1">• Clinical manifestations (most Pts w/o sx)</p>
<p class="noindent2">Type I: <b class="calibre7">hyperviscosity</b> (cold worsens sx) → HA, visual Δ, livedo, digital ischemia</p>
<p class="noindent2">Type II/III: <b class="calibre7">vasculitis</b> (not affected by cold) → fever, derm (54–80%; <b class="calibre7">purpura</b>, livedo reticularis, ulcers), <b class="calibre7">arthralgia</b> (44–70%; symmetric migratory, small/med joints), <b class="calibre7">glomerulonephritis</b> (50%; MPGN), neurologic (17–60%; <b class="calibre7">peripheral neuropathy</b> (polyneuropathy &gt;mononeuritis multiplex), ↓ Hgb, ↓ plt, ↑ B-cell lymphoma risk, GI (5%; pain, HSM, ↑ LFTs). <b class="calibre7">“Meltzer’s triad”:</b> purpura, arthralgias, weakness in 25–30%.</p>
<p class="noindent1">• Dx studies</p>
<p class="noindent2">✓ Cryoglobulins (keep blood <i class="calibre6">warmed to 37</i>°<i class="calibre6">C</i> en route to lab to avoid false ⊖, loss of RF and ↓↓ C3, C4). <i class="calibre6">Cryocrit</i> quantifies cryoprotein but not always indicative of disease activity. May see false ↑ in WBC or plt on automated CBC due to precipitation.</p>
<p class="noindent2">Type I: ✓ serum viscosity, symptomatic if ≥4.0 centipoise; complement normal.</p>
<p class="noindent2">Type II: ↓ <b class="calibre7">C4</b>, variable C3, ↑ ESR, ⊕ RF. ✓<b class="calibre7"> HCV, HBV, HIV</b> in mixed cryoglobulinemia. Bx: hyaline thrombi; small vessel leukocytoclastic vasculitis w/ mononuclear infiltrate.</p>
<p class="noindent1">• Treatment <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2017;129:289;</span> <span class="r2">J Inflamm Res</span> <span class="r1">2017;10:49)</span>: Rx underlying disorder. Heme malig → chemoradiation; HCV → antivirals; CTD → DMARD/steroids ± RTX. Type I: plasma exchange if hyperviscosity; steroids, alkylating agents, RTX, chemo. For mixed cryo, steroids and RTX; CYC or plasma exchange for major organ involvement.</p>
<p class="h">Connective tissue disease–associated vasculitis</p>
<p class="noindent1">• Small-vessel vasculitis a/w <b class="calibre7">RA, SLE,</b> or <b class="calibre7">Sjögren’s syndrome</b></p>
<p class="noindent1">• Clinical sx: distal arteritis (digital ischemia, livedo reticularis, palpable purpura, cutaneous ulceration); visceral arteritis (pericarditis, mesenteric ischemia); peripheral neuropathy</p>
<p class="noindent1">• Dx studies: skin/sural nerve bx, EMG, angiography; ↓ C3, C4 in SLE; ⊕ RF, anti-CCP in RA</p>
<p class="noindent1">• Treatment: steroids, cyclophosphamide, MTX (other DMARDs)</p>
<p class="h">Cutaneous leukocytoclastic angiitis <span class="r1">(</span><span class="r2">Arthritis Rheumatol</span> <span class="r1">2018;70:171)</span></p>
<p class="noindent1">• Most common type of vasculitis; heterogeneous group of clinical syndromes due to <b class="calibre7">IC deposition</b> in capillaries, venules, and arterioles; includes <b class="calibre7"><i class="calibre6">hypersensitivity vasculitis</i></b></p>
<p class="noindent1">• Etiol: <b class="calibre7">drugs</b> (PCN, ASA, amphetamines, levamisole, thiazides, chemicals, immunizations, etc.); <b class="calibre7">infection</b> (<i class="calibre6">Strep</i>, <i class="calibre6">Staph</i>, endocarditis, TB, hepatitis); <b class="calibre7">malignancy</b> (paraneoplastic)</p>
<p class="noindent1">• Clinical manifestations: abrupt onset of <b class="calibre7">palpable purpura</b> and <b class="calibre7">transient arthralgias</b> after exposure to the offending agent; visceral involvement rare but can be severe</p>
<p class="noindent1">• Dx studies: ↑ ESR, ↓ complement levels, eosinophilia; ✓ U/A; <b class="calibre7">skin biopsy</b> → leukocytoclastic vasculitis <b class="calibre7"><i class="calibre6">w/o IgA deposition</i></b> in skin (to distinguish from IgA <i class="calibre6">vasculitis</i>); if etiology not clear, consider ANCA, cryoglobulins, hepatitis serologies, ANA, RF</p>
<p class="noindent1">• Treatment: withdrawal of offending agent ± rapid prednisone taper</p>
<p class="h1cr"><a id="page_8-21" class="calibre8"></a>V<small class="calibre31">ARIABLE</small>-V<small class="calibre31">ESSEL</small> V<small class="calibre31">ASCULITIS</small></p>
<p class="h">Behçet’s syndrome <span class="r1">(</span><span class="r2">Nat Rev Dis Primers</span> <span class="r1">2021;7:67)</span></p>
<p class="noindent1">• <b class="calibre7">Systemic vasculitis</b> affecting all vessel sizes, venous and arterial, a/w painful <b class="calibre7">oral and/or genital ulcers</b></p>
<p class="noindent1">• Epi: usually young adults (25–35 y); ♂ = ♀, ↑ severity in ♂; a/w HLA-B51; ↑ prev on old Silk Road (Turkey, Middle East, Asia) w/ 5 vs. 370/100,000 in U.S. vs. Turkey</p>
<p class="noindent1">• Classification criteria (#1 + ≥2 others is 91% Se &amp; 96% Sp; <span class="r2">Lancet</span> <span class="r1">1990;335:1078</span>)</p>
<p class="noindent2">1. Recurrent <b class="calibre7">oral aphthous ulceration</b> (≥3× in 1 y, usually 1<sup class="calibre19">st</sup> manifestation)</p>
<p class="noindent2">2. Recurrent <b class="calibre7">genital ulceration</b> (labia in females, scrotum in males)</p>
<p class="noindent2">3. <b class="calibre7">Eye lesions:</b> uveitis, scleritis, retinal vasculitis, optic neuritis; <i class="calibre6">may threaten vision</i></p>
<p class="noindent2">4. <b class="calibre7">Skin lesions:</b> pustules, papules, folliculitis, erythema nodosum (scarring)</p>
<p class="noindent2">5. ⊕ pathergy test (prick forearm w/ sterile needle → pustule) (not sensitive in Caucasians)</p>
<p class="noindent1">• Other clinical manifestations: most recur but are not chronic</p>
<p class="noindent2">Arthritis: mild, ± symmetric, nondestructive, involving knees and ankles</p>
<p class="noindent2">Neurologic: usually involvement of midbrain parenchyma; peripheral neuropathy rare</p>
<p class="noindent2">Vascular: superficial or deep vein thrombosis (25%); arterial stenosis, occlusion, and aneurysm can also occur; low incidence of thromboembolism</p>
<p class="noindent1">• Dx studies: ↑ ESR/CRP; ulcer swab to r/o HSV; ulcer bx nonspecific; ophtho eval if sx</p>
<p class="noindent1">• Treatment <span class="r1">(</span><span class="r2">Ann Rheum Dis</span> <span class="r1">2018;77:808)</span></p>
<p class="noindent2">Mucocutaneous: <span class="underline">Mild</span>: <b class="calibre7">topical steroids</b>, <b class="calibre7">colchicine</b> (esp. for erythema nodosum), dapsone, apremilast (PDE-4 inhib) for oral ulcers and ? genital ulcers <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;381:1918)</span>. <span class="underline">Severe</span>: oral steroids, steroid-sparing agents.</p>
<p class="noindent2">Arthritis: NSAIDs, colchicine, steroids, steroid-sparing agents</p>
<p class="noindent2">Ocular: <b class="calibre7">topical and/or systemic steroids</b> ± steroid-sparing agents</p>
<p class="noindent2">Steroid-sparing: AZA, anti-TNF, CYC (large vessel and CNS ds), CsA, MTX, IFNα-2A</p>
<p class="noindent2">Venous thrombosis: steroids and anticoagulation (careful if aneurysm present)</p>
<h2 class="ct"><a id="h112" class="calibre8"></a><a href="part0003.html#rh123" class="calibre8">AUTOINFLAMMATORY SYNDROMES</a></h2>
<p class="noindent2"><i class="calibre6">Immune-mediated diseases thought to result from overactivation of innate immunity</i></p>
<p class="h">Familial Mediterranean fever <span class="r">(FMF)</span> <span class="r1">(</span><span class="r2">Ann Rhem Dis</span> <span class="r1">2016;75:644)</span></p>
<p class="noindent1">• Recessive <i class="calibre6">MEFV</i> mutations (activating pyrin, upstream of inflammasome)</p>
<p class="noindent1">• Febrile episodes for 1–3 d w/ abd pain (serositis, can mimic acute abdomen), pleurisy, lg joint monoarthritis/arthralgia, erysipelas-like skin lesions. Variable time between attacks.</p>
<p class="noindent1">• Epidemiology: ↑ prev in Armenians (1/500), Sephardic Jews, North Africans, Turks, Arabs; onset usually as child</p>
<p class="noindent1">• Risk of ESRD due to amyloidosis (AA), peritoneal adhesions, or infertility if untreated</p>
<p class="noindent1">• Colchicine effective prophylactic and ↓ amyloid; anti-IL1 is alternative <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1908)</span></p>
<p class="h">TNF receptor-associated periodic syndrome <span class="r">(TRAPS)</span></p>
<p class="noindent1">• TNF receptor mutations → febrile episodes q 5–6 wks each lasting &gt;7 d w/ myalgia, abd pain/nausea, migratory rash, periorbital edema; risk of amyloidosis (AA)</p>
<p class="noindent1">• Epidemiology: autosomal dom. w/ variable penetr.; prev 1/million; onset usually as child</p>
<p class="noindent1">• Rx: steroid taper; NSAID alone if mild flare. If freq or severe flares, anti-IL1 (canakinumab) induction and maintenance <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1908)</span> appears more effective than anti-TNF</p>
<p class="h">VEXAS <span class="r">(vacuoles, E</span>1<span class="r"> enzyme, X-linked, autoinflammatory, somatic)</span> syndrome</p>
<p class="noindent1">• Acquired/mosaic <i class="calibre6">UBA1</i> (ubiquitylation enzyme on X chr) mutation in HSCs → myeloid + erythroid cytoplasmic vacuoles → heterogeneous but fever, cytopenias, chondritis, vasculitis, thrombosis, aveolitis, neutrophilic dermatoses common <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:2628)</span></p>
<p class="noindent1">• Epidemiology: ♂, mean onset age &gt;60</p>
<p class="noindent1">• Steroids reduce symptoms but Rx otherwise unclear</p>
<p class="h">Hemophagocytic lymphohistiocytosis<span class="r"> (HLH)</span></p>
<p class="noindent1">• ↑↑ immune activity; failure to ↓ activated macrophages by NK cells/CTLs → ↑ cytokines (IFNλ, IL18) → macrophages phagocytize other blood cells, cytokine storm, organ failure</p>
<p class="noindent1">• Triggered by disruption of immune homeostasis: immune activation (infxn, autoimmune flare) or immunodeficiency; ~25% familial (mutations in perforin-mediated cytotoxicity)</p>
<p class="noindent1">• HLH 2/2 rheumatologic disease termed macrophage activation syndrome (MAS)</p>
<p class="noindent1">• Fever, ↑ spleen, cytopenias, ↑ TG, ↓ fibrinogen, ↑ LFTs, hemophagocytosis, ↓ NK cell activity, ↑ ferritin, ↑ soluble IL2R; H-score for HLH likelihood <span class="r1">(</span><span class="r2">Arthritis Rheum</span> <span class="r1">2014;66:2613)</span></p>
<p class="noindent1">• Rx trigger (eg, rheum flare w steroids/biologics); if insufficient, HLH-04 protocol (etoposide + steroids ± CsA ± intrathecal MTX; BMT if genetic or relapsed/refractory; <span class="r2">Blood</span> <span class="r1">2017;130:2728</span>), anti-IL1/IVIg/steroids <span class="r1">(</span><span class="r2">Lancet Rheumatol</span> <span class="r1">2020:2:e358)</span>, or emapalumab (anti-IFNγ) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:1811)</span>; high mortality if no Rx <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2019;133:2465)</span></p>
<h2 class="ct"><a id="h113" class="calibre8"></a><a id="page_8-22" class="calibre8"></a><a href="part0003.html#rh124" class="calibre8">AMYLOIDOSIS</a></h2>
<p class="center"><i class="calibre6">Deposition of misfolded proteins as insoluble fibrils (β-pleated sheets) in normal tissues</i></p>
<p class="imaget"><img src="../images/00107.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">(<i class="calibre6">NEJM</i> 2007;356:2361; 2020;282:1567; <i class="calibre6">Circulation</i> 2020;142:e7; <i class="calibre6">Nat Rev Dis Primers</i> 2018;4:38)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre13"/>
<col class="calibre12"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Clinical Manifestations of Amyloidosis</b> <span class="sm">(<i class="calibre6">Lancet</i> 2016;387:2641; <i class="calibre6">JAMA</i> 2020;324:79)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">System</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Manifestations</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Amyloid</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renal</b></p></td>
<td class="th1"><p class="tbody">Proteinuria or nephrotic syndrome</p></td>
<td class="th1"><p class="tbodyc">AL, AA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiac</b></p></td>
<td class="th1"><p class="tbody">Restrictive CMP (↓ EF late), thick walls but ↓ QRS amplitude, conduction abnl, AF, syncope</p></td>
<td class="th1"><p class="tbodyc">AL, mATTR, wt ATTR</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GI</b></p></td>
<td class="th1"><p class="tbody">Diarrhea, malabsorption, protein loss; ulcers, hemorrhage, obstruction; macroglossia (dysphonia/dysphagia)</p></td>
<td class="th1"><p class="tbodyc">All systemic</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Neuro</b></p></td>
<td class="th1"><p class="tbody">Periph neuropathy w/ painful paresthesia; carpal tunnel;</p>
<p class="tbody">Autonomic neuro → impotence, dysmotility, ↓ BP</p></td>
<td class="th1"><p class="tbodyc">mATTR, Aβ<sub class="calibre17">2</sub>M, AL, localized</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Skin</b></p></td>
<td class="th1"><p class="tbody">Waxy, nonpruritic papules; periorbital ecchymoses; “pinch purpura” = skin bleeds with minimal trauma</p></td>
<td class="th1"><p class="tbodyc">AL</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">HSM</b></p></td>
<td class="th1"><p class="tbody">Hepatosplenomegaly w/o hepatic dysfnx or cytopenias</p></td>
<td class="th1"><p class="tbodyc">All systemic</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Endo</b></p></td>
<td class="th1"><p class="tbody">Deposition with rare hormonal insufficiency</p></td>
<td class="th1"><p class="tbodyc">localized</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">MSK</b></p></td>
<td class="th1"><p class="tbody">Arthralgias and arthritis (especially shoulder)</p></td>
<td class="th1"><p class="tbodyc">AL, Aβ<sub class="calibre17">2</sub>M</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulm</b></p></td>
<td class="th1"><p class="tbody">Airway obstruction; pleural effusions</p></td>
<td class="th1"><p class="tbodyc">AL, AA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Heme</b></p></td>
<td class="th1"><p class="tbody">Factor X deficiency</p></td>
<td class="th1"><p class="tbodyc">AL</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Biopsy (abd fat pad, rectal, etc.): apple-green birefring w/ <b class="calibre7">Congo red</b> (Se &lt;85% Sp &gt;90%)</p>
<p class="noindent1">• If suspect AL: SPEP &amp; UPEP + immunofixation, free light chains, ± BM biopsy</p>
<p class="noindent1">• If suspect renal involvement: U/A for proteinuria</p>
<p class="noindent1">• If suspect CMP: ECG (↓ volt, conduction abnl), TTE (↓ longitudinal strain, LVH, valve &amp; septal thickening, myocard. speckling), MRI (late gad. enhancement). R/o plasma cell dyscrasia; if ⊖ → (99m)Tc-pyrophosphate (PYP) SPECT for TTR. ± Cardiac bx.</p>
<p class="noindent1">• Mass spec of biopsy to ID fibril type. Genetic testing to distinguish wt vs. hereditary ATTR.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre39"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Treatment of Amyloidosis</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">AL</p></td>
<td class="th1"><p class="tbodyh">Limited involvement: high-dose <b class="calibre7">melphalan</b> → <b class="calibre7">auto HSCT</b> <span class="sm">(<i class="calibre6">NEJM</i> 2007;357:1083)</span></p>
<p class="tbodyh">Not HSCT candidate: dara-CyBorD [daratumumab + CYC + bortezomib + dexameth.] <span class="sm">(<i class="calibre6">NEJM</i> 2021;385:46)</span>. [Low-dose melphalan + D] if Bor not tolerated.</p>
<p class="tbodyh">Relapse: dara, ixazomib, Bor, or lenalidomide <span class="sm">(<i class="calibre6">Blood</i> 2020;136:2620)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">AA</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Rx underlying disease.</b> Colchicine for FMF, esp. to ↓ renal dis. ? Anti-cytokine Rx (anakinra or tocilizumab) <span class="sm">(<i class="calibre6">Clin Exp Rheumatol</i> 2015;33:46; <i class="calibre6">Amyloid</i> 2017;24:189)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">ATTR</p></td>
<td class="th1"><p class="tbodyh">Stabilize TTR tetramers: diflunisal slows neuropathy; tafamidis ↑ QoL, ↓ CV hosp/mortality <span class="sm">(<i class="calibre6">JAMA</i> 2013;310:2658; <i class="calibre6">NEJM</i> 2018;379:1007)</span></p>
<p class="tbodyh">↓ hepatic mut TTR production: siRNA (patisiran) or anti-sense oligo (inotersen) -improve neuropathy <span class="sm">(<i class="calibre6">NEJM</i> 2018;379:11 &amp; 22)</span>; CRISPR in trials <span class="sm">(<i class="calibre6">NEJM</i> 2021;385;493)</span></p>
<p class="tbodyh">Liver transplant can benefit some mATTR forms <span class="sm">(<i class="calibre6">Muscle Nerve</i> 2013;47:157)</span></p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Clearance of amyloid by Ab under study <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:1106;</span> <span class="r2">Br J Haematol</span> <span class="r1">2020;189:228)</span></p>
<p class="noindent1">• Cardiac: diuretics; avoid CCB; ↑ dig toxicity risk (? amyloid binding); anticoag all AF</p>
<p class="noindent1">• Heart, kidney, and liver transplant may be considered in those w/ advanced disease</p>
<p class="noindent1">• Median survival: 5y AL (~6 m if CM); 11y AA; 4y wt ATTR &amp; 2.5y <i class="calibre6">ATTR</i> V122I CM w/o Rx</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0013.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0015.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
